2-7-2019

Functional random forest with applications in dose-response predictions

Raziur Rahman

Saugato Rahman Dhruba

Souparno Ghosh

Ranadip Pal

SCIENTIFIC REPORTS

OPEN

Functional random forest with applications in dose-response predictions

Received: 29 May 2018
Accepted: 20 December 2018
Published online: 07 February 2019

Raziur Rahman[1], Saugato Rahman Dhruba[1], Souparno Ghosh[2] & Ranadip Pal[1]

Drug sensitivity prediction for individual tumors is a significant challenge in personalized medicine. Current modeling approaches consider prediction of a single metric of the drug response curve such as *AUC* or IC_{50}. However, the single summary metric of a dose-response curve fails to provide the entire drug sensitivity profile which can be used to design the optimal dose for a patient. In this article, we assess the problem of predicting the complete dose-response curve based on genetic characterizations. We propose an enhancement to the popular ensemble-based Random Forests approach that can directly predict the entire functional profile of a dose-response curve rather than a single summary metric. We design functional regression trees with node costs modified based on dose/response region dependence methodologies and response distribution based approaches. Our results relative to large pharmacological databases such as CCLE and GDSC show a higher accuracy in predicting dose-response curves of the proposed functional framework in contrast to univariate or multivariate Random Forest predicting sensitivities at different dose levels. Furthermore, we also considered the problem of predicting functional responses from functional predictors *i.e.*, estimating the dose-response curves with a model built on dose-dependent expression data. The superior performance of Functional Random Forest using functional data as compared to existing approaches have been shown using the HMS-LINCS dataset. In summary, Functional Random Forest presents an enhanced predictive modeling framework to predict the entire functional response profile considering both static and functional predictors instead of predicting the summary metrics of the response curves.

Precision medicine plays an important role in the push towards advancing cancer therapy. A significant step in the process involves mapping genetic characterizations to the applied drug sensitivity response. A multitude of approaches have been proposed to address the issue of predictive modeling of drug sensitivity but the results still indicate a significant scope for improvement[1–4]. Crowd-sourced initiatives such as NCI-DREAM conducted Drug Sensitivity Prediction Challenge[2] enabled the performance evaluation of multiple algorithms on the same dataset while being restricted to smaller number of samples. Recently, a number of pharmacological databases[1,5,6] have been made public to assist researchers in validating their predictive algorithms using larger biological datasets.

Drug sensitivity information in the form of responses for different doses represented as a curve is becoming more prevalent for cancerous cell lines with the advent of advanced data collection techniques. Such datasets are often referred as *functional* data[7]. Typical approaches for sensitivity prediction predict a summary metric of the entire drug response curve such as *Area Under the Curve* (*AUC*) or IC_{50}. The problem of predicting a summary metric of the drug response curve has been tackled using a diverse set of regression approaches such as linear regression with regularization, nonlinear regression, kernel based techniques and ensemble based approaches[2,8–10]. Additionally, drug sensitivity prediction modeling has also been proposed based on features extracted using Principal Component Analysis (PCA)[11].

A primary concern in using a certain drug sensitivity response summary metric is that they fail to describe the entire dose-response effect *i.e.*, they represent just a particular scenario such as the drug concentration to achieve 50% cell viability (IC_{50}) or the inflection point of the dose-response fitted curve (EC_{50}) or the maximal activity reached in the curve (A_{max})[1] or the area under the fitted curve (*AUC*). Meanwhile, various functional regression models have been proposed in other research areas to predict the entire response curve[12]. Yu *et al.*[13] have presented each response curve as a linear combination of known basis functions and grown regression trees using

Souparno Ghosh,
IANR, Statistics,
University of Nebraska-Lincoln,
sghosh5@unl.edu

[1]Texas Tech University, Department of Electrical and Computer Engineering, Lubbock, Texas, 79409, USA. [2]Texas Tech University, Department of Mathematics and Statistics, Lubbock, Texas, 79409, USA. Correspondence and requests for materials should be addressed to R.P. (email: ranadip.pal@ttu.edu)

the coefficients of this expansion, while Nerini *et al.*[14] have proposed functional PCA in the classification method for easy representation of regression trees. The knowledge of the entire drug response curve can answer clinically relevant questions such as what will be the sensitivity at the highest non-toxic dose concentration (toxicity can be estimated using experimentations on normal cells or computational modeling) or the sensitivity at the drug concentration available at the targeted organ (pharmacokinetics estimated using micro-dosing) for that specific patient? Furthermore, a summary metric such as AUC for two different dose response curves might be same even when they might offer different information such as very high sensitivity for high doses for drug A as compared to relatively moderate sensitivity over all drug doses for drug B. Note that drug A at high doses might be better in killing most cancer cells as compared to drug B which will not be apparent through AUC prediction.

Thus, there is a need for entire dose response curve prediction which is not handled directly by existing regression models. In one of our previous works[15], we have used each dose-response point to build individual regression models for prediction purposes. However, the individual models lack incorporation of the continuous nature of the dose-response curve. In this paper, we are proposing the incorporation of dose-response points or distributions in the generation of regression tree node cost and leaf nodes to improve the accuracy of Random Forest (RF) model for sensitivity prediction. At each regression tree node, region-wise response points or distributions (Gaussian) are considered to calculate the node cost. The leaf nodes store the functional data used to predict the entire dose-response profile for test samples, while the model input consists of genomic characterization in regular form or continuous curve form. We present methodologies that can consider both regular and functional inputs. For analysis purposes, each response curve has been approximated by a linear combination of B-spline functions[13] and thus, the framework can also be applied in scenarios different from drug sensitivity prediction. We validate our proposed *Functional Random Forest* (FRF) approach using data from the well-known pharmacological databases of Cancer Cell Line Encyclopedia (CCLE)[1] and Genomics of Drug Sensitivity for Cancer (GDSC)[5].

The article is organized as follows: The Materials and Methods section compiles the basic steps involved in designing FRF models while discussing the impact of storing functional data in forest leaf nodes and highlighting the region-wise node cost procedures. The Results section provides the performance evaluation of FRF model for both synthetic experiments and actual pharmacological data. Furthermore, it also presents the biological importance of genes selected by FRF. Finally, the Discussion section points out the advantages of using FRF to predict the dose-response curves in the larger context of drug sensitivity prediction and provides possible future research directions.

Materials and Methods

The idea of Functional Random Forest is based on regular regression tree based Random Forest. Thus, we will first describe the design procedure for regular regression trees and subsequently present the construction of functional regression tree based FRF approach. Before delving into the details of tree construction, we describe the datasets used for this study which will help us establish a number of theoretical assumptions in the methodology.

Datasets and Preprocessing. For our experiments, we have considered two most comprehensive publicly available cancer pharmacogenomics databases: Cancer Cell Line Encyclopedia (CCLE)[1] and Genomics of Drug Sensitivity for Cancer (GDSC)[5]. CCLE database was generated by Broad Institute and Novartis Institutes for Biomedical Research. This database includes genetic and pharmacological characterization of 947 human cancer cell lines, together with pharmacological profiling of 24 small molecules (anticancer compounds) across ~500 of these cell lines that encompasses 36 tumor types[1]. The response of a cell line to a specific drug is reported for 7 to 8 dose points ranging from 0.0025 μM to 8 μM. Additionally, four different drug sensitivity measures EC_{50}, IC_{50}, A_{max} and AUC are listed. Note that these measures are features of a dose-response curve fitted from the observed dose-response points. GDSC database was created as part of the Cancer Genome Project[5] and contains gene expression data for 789 cell lines and drug responses for 714 cell lines. Each cell line has 22,277 probe sets for gene expression yielding a high dimensional feature space. Similar to CCLE, each cell line's response to the drugs are reported for 7 to 9 dose points where minimum dose ranges from 3×10^{-5} μM to 15.625 μM and maximum dose ranges from 0.008 μM to 4000 μM. For our experiment, we utilize GDSC *v*5 that lists two drug sensitivity measures IC_{50} and AUC along with 105 different IC values for different levels of cell viability from 0.1% to 100% in each cell line for each drug. Note that these IC values are extracted from the complete dose-response curves fitted from the observed dose-response points and extrapolated to 100% cell viability as the curves do not reach 100% at maximum dose for most cell line–drug pairs. Both CCLE and GDSC provide observed dose-response points or fitted curve points which could be utilized as our functional response data. However, the genomic characterization data are available in the stationary format as the expressions are measured before any drug application. Therefore, to demonstrate the functional input and output scenario for our FRF model, we have used data from the Harvard Medical School Library of Integrated Network-Based Cellular Signatures (HMS-LINCS) database, which to our knowledge, is the only publicly available source offering functional responses as well as predictors. HMS-LINCS offers genomic characterization data in the form of Reverse Phase Protein Array (RPPA) expression data for 21 proteins where Phosphorylation state and protein levels were measured in 10 $BRAF^{V600E/D}$ melanoma cell lines at 7 different doses and 5 different time points[16]. The cellular response data consists of viability and apoptosis measured in the same cell lines using Fluorescence imaging apoptosis assay for the same 7 doses but 3 different time points[16]. The database contains data for 9 $BRAF^{V600E}$ and 1 $BRAF^{V600D}$ melanoma cell lines that were exposed to 4 RAF inhibitors and 1 MEK inhibitor at 7 different doses ranging from 3.2 nM to 3.2 μM. Protein expression data is available for 5 different time points: 1, 5, 10, 24 and 48 hours post drug application and apoptosis data is available for 24, 48 and 72 hours post drug application. For compound sensitivity assessment, two different measures are available: relative viability and mean apoptosis fraction, computed using the number of apoptotic cells and the total number of cells normalized with the DMSO control[16,17].



Figure 1. Pictorial representation of the commonly used genomic and functional characterizations.

Figure 1 illustrates the pictorial representations of genomic and functional characterizations data, where the left half shows the static and functional format of genomic characterizations and the right half demonstrates the dose-response curves for various cell line–drug pairs and different summary metrics extracted from such a curve.

Random Forest Regression. Random Forest consists of a set of T un-pruned ensemble of regression trees[18] that are generated based on bootstrap sampling from the original training data. The bootstrap resampling of the data for training each tree increases the diversity between the trees. Each tree is composed of root node, branch nodes and leaf nodes. For each node of a tree, the optimal node splitting feature is selected from a set of m features that are again randomly selected from a feature space of size M. If $m \ll M$, the selection of the node splitting feature from a random set of features decreases the correlation between different trees and thus, the average response of multiple regression trees is expected to have lower variance than the individual regression trees. However, there exists a trade-off as a larger m can improve the predictive capability of individual trees but also can increase the correlation between trees and void any gains from averaging multiple predictions.

Process of splitting a node. Let $x_{tr}(i, j)$ and $y(i)$ denote the training input feature j and output response, respectively, for sample i where $i = 1, 2, \ldots, n,\ j = 1, 2, \ldots, M$. At any node η_P, we aim to select a feature j_s from a random set of m ($<M$) features and a threshold z to partition the node into two child nodes η_L (left node with samples satisfying $x_{tr}(i \in \eta_P, j_s) \leq z$) and η_R (right node with samples satisfying $x_{tr}(i \in \eta_P, j_s) > z$). We consider the node cost as sum of square deviances (SSD), *i.e.*

$$D(\eta_P) = \sum_{i \in \eta_P} (y(i) - \mu(\eta_P))^2 \tag{1}$$

where $\mu(\eta_P) = \mathbb{E}[y(i \in \eta_P)]$, $\mathbb{E}[\cdot]$ denotes the Expected value. Thus, the reduction in cost (*i.e.*, *reward* function) for partition γ at node η_P is given in Eq. (2), where the goal is to select the partition $\gamma^* \in \eta_P$ that maximizes the reward *or*, minimizes the cost.

$$\begin{aligned} C(\gamma, \eta_P) &= D(\eta_P) - D(\eta_L) - D(\eta_R) \\ \gamma^* &= \underset{\gamma}{\text{argmax}}\, C(\gamma, \eta_P) \end{aligned} \tag{2}$$

Note that for a continuous feature with n samples, a total of n partitions needs to be checked *i.e.*, the computational complexity of each node split is $O(mn)$. During tree generation, a node with $n \leq n_{size}$ samples is not partitioned any further where n_{size} is a pre-specified sample size threshold.

Several other approaches have been proposed for tree construction such as applying *Principal Component Analysis* (*PCA*)[19] in the response matrix[13]. The principal components (PC) not only serve the purpose of dimensionality reduction but is also expected to increase the robustness of the trees. Here, the node cost used to build the trees is given by

$$D(\eta_p) = \sum_{i \in \eta_p} (\zeta(i) - \bar{\zeta}(r))^T (\zeta(i) - \bar{\zeta}(r)) \tag{3}$$

where $\zeta(i)$ denotes a PC based response vector and $\bar{\zeta}(r)$ is the mean vector of PCs[14]. Yu *et al.*[13] have also considered the use of basis functions to represent the response variables with the node cost written as

$$D(\eta_p) = \sum_{i \in \eta_p} (\mathbf{c}(i) - \mu_c(\eta_p))^T \Phi (\mathbf{c}(i) - \mu_c(\eta_p)) \tag{4}$$

where $\mathbf{c}(i)$ denotes the vector of basis coefficients, $\mu_c(\eta_p) = \mathbb{E}[\mathbf{c}(i)]$ and Φ denotes the matrix of basis vector inner products[14].

Forest Prediction. Using the randomized feature selection process, we fit the tree based on *bootstrap* samples $\{(\mathbf{X}_1, Y_1), (\mathbf{X}_2, Y_2), \ldots, (\mathbf{X}_n, Y_n)\}$ from training data. Let us consider the prediction based on a test sample $\mathbf{x}$ for the tree Θ. Assume that $\tilde{\gamma}(\mathbf{x}, \Theta)$ be the partition containing $\mathbf{x}$, the tree response takes the following form[18,20,21] with corresponding weights $w_i(\mathbf{x}, \Theta)$

$$y(\mathbf{x}, \Theta) = \sum_{i=1}^{n} w_i(\mathbf{x}, \Theta) y(i) \tag{5}$$

$$w_i(\mathbf{x}, \Theta) = \frac{\mathbf{1}_{\{\mathbf{x}_{tr}(i) \in \tilde{\gamma}(\mathbf{x}, \Theta)\}}}{\#\{r: \mathbf{x}_{tr}(i) \in \tilde{\gamma}(\mathbf{x}_{tr}(r), \Theta)\}} \tag{6}$$

Let the T trees of RF be denoted by $\Theta_1, \Theta_2, \ldots, \Theta_T$ and $w_i(\mathbf{x})$ to be the average weights over the forest. Then, the average RF prediction for the test sample $\mathbf{x}$ is given by weighted average of predictions of all T trees using the weight vector in (7).

$$w_i(\mathbf{x}) = \frac{1}{T} \sum_{j=1}^{T} w_i(\mathbf{x}, \Theta_j) \tag{7}$$

$$\hat{y}(\mathbf{x}) = \sum_{i=1}^{n} w_i(\mathbf{x}) y(i) \tag{8}$$

Multivariate Random Forest. Multivariate Random Forest (MRF)[10] is the extension of the regular RF for joint prediction of multivalued output responses that can be useful in different response scenarios. The primary difference between MRF and the regular RF is in the tree generation step where the node cost is different from $D(\eta_p)$ in Eq. (1). In a multivariate output scenario, the difference between a sample point response and the multivariate mean distribution is desirable and can be achieved by using the SSD of the *Mahalanobis distance* measure.

$$\begin{aligned} D_{MRF}(\eta_p) &= \sum_{i \in \eta_p} (\mathbf{y}(i) - \mu(\eta_p))^T \Sigma^{-1} (\mathbf{y}(i) - \mu(\eta_p)) \\ \text{where } \mathbf{y}(i) &= [y(i, 1)\ y(i, 2)\ \cdots\ y(i, m)] \end{aligned} \tag{9}$$

where Σ is the covariance matrix, m denotes the number of response points, and $\mu(\eta_p) = \mathbb{E}[\mathbf{y}(i \in \eta_p)]$. The inverse covariance matrix Σ^{-1} is a precision matrix that provides a measure of conditional dependence between multiple random variables. For our analysis, we consider MRF modeling on 8 dose-response points similar to our earlier published study[15].

Functional Random Forest. Regular classification and regression trees (CART) work on non-functional variables *e.g.*, discrete gene expression values and summary metrics shown in Fig. 1. In this section, we consider incorporating functional responses (*e.g.*, dose-response curves shown in right half of Fig. 1) for building functional random forest (FRF). For this purpose, we have introduced two novel alterations in the regression trees–first, in node cost calculation and second, in regression of the leaf node samples.

Node cost calculation. For the construction of regular regression tree based models, partitioning and accuracy measure for each node η_p is achieved using the *deviance criterion* in Eq. (1). However, this criterion only considers a single parameter (μ) of the drug sensitivity response while neglecting the shapes of the dose-response curves at each node. To incorporate the shape information of a dose-response curve into the deviance calculation, we

propose to *discretize* the entire curve into multiple regions to calculate the node cost in each region separately and then sum the individual deviances to get the total deviance at each node, *i.e.*

$$\hat{D}_{FRF}(\eta_p) = \sum_{j=1}^{q} \hat{D}_r(r_j) \tag{10}$$

where $\hat{D}_r(r_j)$ is the deviance calculated from the j^{th} region r_j, and q is the total number of regions. For the discretization scheme, we choose to discretize the coordinate values as appropriate for the observed data (*e.g.*, we use the 8 given dose points to divide the dose-response curves into 8 regions in CCLE as compared to GDSC where we utilize the ~100 *IC* response values for discretization). Furthermore, we propose two distinct algorithms for node cost calculation where (i) either the observed dose-response points are used directly or, (ii) the underlying distribution is extracted from these points and various divergence criteria are applied.

Node cost calculation using dose-response points. For this approach, we use the observed dose-response data directly and assume the complete curve to be made up of multiple regions each belonging to an observed dose point or response point. Then, the total deviance at each node η_P is measured by calculating the SSD per region[14] as a measure of $\hat{D}_r(r_j)$ and subsequently using (10).

$$\hat{D}_r(r_j) = \sum_{i \in \eta_p} \|y_j(i) - \overline{y}_j\|^2 \tag{11}$$

where $y_j(i)$ denotes the response in region r_j at dose d_j for sample i, and $\overline{y}_j = \mathbb{E}[y_j(i \in \eta_p)]$. The criterion described in Eq. (11) considers the region-wise differences rather than the difference in an overall feature of the curve.

Node cost calculation using dose-response distributions. In the previous approach, each region consists of $n_P = \sum_{i \in \eta_p} i$ response points (*i.e.*, the number of cell lines examined for the applied drug) at a specific dose d_j and these discrete responses are used to compute the node deviance in (10). However, if a study performs multiple experiments at a certain dose for each individual cell line (*i.e.*, technical replicates), we can potentially generate a distribution from all the replicates at that specific dose. Therefore, instead of considering a single response value $y_j(i)$ for cell line i at dose d_j, we can alternatively calculate the node cost by approximating the response by a probability distribution, f_j. The modified splitting criterion for this scenario is given by

$$\hat{D}_r(r_j) = \sum_{i \in \eta_p} C_f(\Phi_i, \hat{\Phi}) \tag{12}$$

$$\text{where } C_f(\Phi_i, \hat{\Phi}) = \sum_{\Omega} \hat{\Phi} f_j\left(\frac{\Phi_i}{\hat{\Phi}}\right) \tag{13}$$

Here, $C_f(\cdot, \cdot)$ is called the *f-divergence* of the probability distribution, Ω is the distribution range, and $\hat{\Phi}$ is the mean distribution at node η_P derived using mixture distribution[9]. There are various ways to calculate the *f-divergence* depending on the divergence measure $f_j(u)$ in Eq. (13). For instance, the *Kullback-Leibler* (*KL*) *divergence*[22] is obtained with $f_j(u) = u\ln(u)$

$$K_f(\Phi_i, \hat{\Phi}) = \sum_{\Omega} \Phi_i \ln\left(\frac{\Phi_i}{\hat{\Phi}}\right) \tag{14}$$

And, the *Hellinger Distance*[23] is generated using $f_j(u) = (\sqrt{u} - 1)^2$

$$H_f(\Phi_i, \hat{\Phi}) = \sum_{\Omega} \left(\sqrt{\Phi_i} - \sqrt{\hat{\Phi}}\right)^2 \tag{15}$$

Functional regression using dose-response curves. Regular regression tree response for a new sample is based on averaging the responses in the leaf node reached by the new sample. Since the responses considered in a regular regression tree are individual points, a simple averaging of the values suffices. For our FRF scenario, each leaf node consists of a set of functional responses and therefore, we need to modify the final prediction as described below.

Given that we have dose-response points, we can potentially fit a spline curve through these points to represent the dose-response as a continuous curve. In recent pharmacological studies, the curve fitting normally consists of sigmoidal, linear or constant functions[1]. In our algorithm, we have considered the *generalized B-spline* fitting for the dose-response curves. To perform Functional Random Forest (FRF) prediction using the spline-fitted curves, we store the curve points for each sample in the leaf nodes instead of a specific feature (*i.e.*, IC_{50} or *AUC*). In the prediction step, for a test sample $\mathbf{x}$, we consider the training response set $\mathbf{y}_j = y_j(i \in \eta_p)$ at each dose d_j separately from the stored dose-response curves in node η_P and fit a Gaussian distribution N_j. The mode of this distribution (*i.e.*, peak) indicates the highest response probability for $\mathbf{x}$ at d_j and we pick the corresponding response value $\hat{y}_j$ as our final prediction.



Figure 2. Drug sensitivity probability distributions at a node for Functional Random Forest prediction where the asterisks (*) indicate modes of distributions at 8 dose points ranging from 0.0025 μM to 8 μM.

$$\begin{aligned} \mathbf{y}_j &\sim N_j(\mathbf{y};\ \mu_j,\ \sigma_j^2) \ \text{ where } \ \mu_j := \mathbb{E}[\mathbf{y}_j],\ \ \sigma_j^2 := \mathrm{Var}[\mathbf{y}_j] \\ \hat{y}_j(\mathbf{x}) &= \underset{y}{\mathrm{argmax}}\, N_j(\mathbf{y};\ \mu_j,\ \sigma_j^2) \end{aligned} \tag{16}$$

The process is then repeated for all dose levels to generate the functional prediction, $\hat{\mathbf{y}}(\mathbf{x})$. Figure 2 illustrates a representative case where the different response probability distributions are displayed for multiple dose levels. Here, the asterisks (*) on the 3D surface denote the distribution modes at different doses that are used to perform the functional prediction. Subsequently, we can use this predicted curve to estimate the conventional drug sensitivity measures such as *AUC*, IC_{50} and EC_{50}.

Function-to-function regression with FRF. Drug sensitivity predictive algorithms normally train regression models on genomic characterizations represented by stationary values such as pre-treatment gene expression (Fig. 1). However, if gene (or protein) expression can be measured post drug application at different doses and/or various time points, the input variables can be modeled as curves representing the dose-expression functions at the corresponding dose points. An example of such functional data is shown in lower left half of Fig. 1 where the functional input-output data is obtained from the HMS-LINCS[16,17] database. In this section, we consider a scenario where the HMS-LINCS protein expressions following drug administration is available along with the resulting dose-responses in terms of cell viability.

Here, we consider a couple of ways to convert the functional data into functional features which are eventually used as model inputs. Similar to the drug sensitivity summary metrics generated from the dose-response curves, we can use the genomic characterization curve to extract features such as *AUC* and IC_{50}. For calculating *AUC*, a reference line (similar to the zero viability line for drug sensitivity) is required and we utilize the available DMSO-treated control RPPA data[16] for this purpose. Figure S1 displays a representative dose-expression curve post drug application with the DMSO-treated control line where the shaded area in between is the desired *AUC*. For this representative protein (p-S6), the expression values are decreasing with increases in dose levels which is the most common scenario. However, for a few cases, the protein expressions either remain almost similar or go up as dose increases. For such proteins, we only consider the expression values below our reference DMSO-treated control line (Fig. 3). Along with *AUC*, we also calculate different *IC* values *i.e.*, IC_{25}, IC_{50} and IC_{75} to be considered as predictor features. To arrive at the *IC* values, we perform 3^{rd} degree polynomial fitting on the observed protein expression data at different doses and record the different *IC* values using the corresponding percentile points between the lowest and highest expression values (*e.g.*, IC_{25} is the dose where the 25^{th} percentile point is located). Figure 3 illustrates three representative protein expression fitted curves with corresponding IC_{25}, IC_{50} and IC_{75} points demonstrating the different behaviors described above *i.e.*, expression values are either (a) mostly decreasing, (b) almost unchanged, or (c) mostly increasing with dose.

Another way of extracting the functional curve features is to rank the curves according to their slopes (*i.e.*, rate of change). Furthermore, a curve can be ranked by its position compared to the other curves *i.e.*, if a curve contains >50% dose points with higher protein expression values compared to another curve, the former will get a higher rank than the later and the process will go on until all curves are ranked.

Accession codes. Source code for Functional Random Forest is available at: https://github.com/razrahman/Functional-Random-forest.

Results

In this section, we apply Functional Random Forest modeling on both synthetic and experimental datasets for performance evaluation and comparison analysis with both univariate and Multivariate Random Forest models.



Figure 3. Illustration of obtaining different *IC* values using observed protein expression points and the corresponding 3^{rd} degree polynomial fitted curve overlaid after AZ-628 administration in cell line C32 for (**a**) protein *p-S6* with a decreasing trend, (**b**) protein *p-mTOR* with minor changes, and (**c**) protein *cPARP* with an increasing trend.

Application of FRF on synthetic data. We first evaluate the performance of FRF using a synthetic experiment. The design matrix has been generated by extracting 10 different features from five different clusters. Each cluster is derived from a Gaussian distribution and the range of the distribution for each cluster has limited overlap with others. Furthermore, we add 10 additional noise features to increase the correlation between samples from different clusters. Subsequently, we have a design matrix of size 75×20 (15 samples each from 5 clusters and 20 covariates with 10 relevant & 10 spurious features). For the output, we create a target matrix of size 75×101 where 101 is the number of different synthetic dose levels. The response values are sampled from the 4-parameter sigmoidal model[1] in Eq. (17) and shown in Fig. 4 for both noiseless and noisy cases, *i.e.*

$$y(d) = A_0 + \frac{A_{\max} - A_0}{1 + \left(\frac{IC_{50}}{d}\right)^{\theta}} \tag{17}$$

where A_0, $A_{\max}$ & θ are fixed but IC_{50} differs slightly for each curve in a certain cluster while d is the applied dose level. We also look into the effect of additive noise in targets as shown in Fig. 4 where (a) displays the target curves *without* noise, and (b) displays the targets with 5% *additive noise*. Table 1 shows the performance of FRF as compared to regular RF for different numbers of trees, folds and noise levels (%). From Table 1, we observe that FRF displays an overall superior performance to RF in all cases, especially improving the model performance by as much as 25% as the noise level increases. A potential reason for this performance boost is the ability of FRF to incorporate the *shape* of the response curves, as shown in Fig. 5(a) where FRF is able to follow a noisy synthetic data curve which RF fails to predict, especially for higher doses.

Application of FRF on biological data. For performance evaluation of Functional Random Forest using actual biological data, we have used three different sources– CCLE, GDSC and HMS-LINCS. The sections below provide the results and corresponding discussion for all three databases.

Application on CCLE dataset. CCLE provides cell line sensitivity data with 7 to 8 dose-response points. For our analysis, we consider the cell lines with 8 points only and thus, we have 8 different regions for node cost calculation in Eq. 10. Tables 2 and 3 display the predictive performance of FRF for both node cost calculation algorithms *i.e.*, using observed dose-response points and underlying distributions. For node cost calculation using distributions, we provide results for both KL divergence and Hellinger distance measures in Eqs (14 and 15). Additionally, we compare the results from the FRF models with standard RF methodology. Tables 2 and 3 provide overall performance comparisons for three different models: (a) regular Random Forest (RF), (b) Functional Random Forest with conventional averaging at the Leaf node (FRFL), and (c) Functional Random Forest with averaging of the dose-response curves at the leaf node (FRF). Note that FRF considers the functional curves for both node cost evaluation *and* response prediction at the leaf nodes, whereas FRFL considers the functional curves for node cost



Figure 4. Synthetic dose-response curve examples– (**a**) without noise, (**b**) 5% additive noise.



Figure 5. Performance comparison for Functional Random Forest and Random Forest for both synthetic data and CCLE data. (**a**) For noisy synthetic data, FRF can follow the actual response variations even though it was modeled using noisy data while RF fails to follow the trend in higher dose levels, (**b**) For fitted dose-response curve in CCLE Liver cell line SNU449 post Erlotinib administration, FRF prediction again outperforms RF prediction.

		Noiseless		5% Noise		10% Noise		20% Noise	
#Trees	#Folds	RF	FRF	RF	FRF	RF	FRF	RF	FRF
50	5	0.037	**0.029**	0.039	**0.034**	0.045	**0.034**	0.063	**0.051**
	10	0.036	**0.028**	0.034	**0.028**	0.043	**0.035**	0.060	**0.049**
100	5	0.039	**0.030**	0.039	**0.034**	0.044	**0.036**	0.063	**0.049**
	10	0.036	**0.029**	0.035	**0.030**	0.042	**0.035**	0.059	**0.047**
150	5	0.041	**0.034**	0.036	**0.030**	0.047	**0.037**	0.060	**0.049**
	10	0.031	**0.027**	0.034	**0.029**	0.042	**0.034**	0.060	**0.047**
Improvement			24%		17%		25%		25%

Table 1. Normalized Mean Absolute Errors (NMAE) for prediction of synthetic data dose-responses with varying noise levels using RF and FRF. The different numbers of folds are used in training & test data separation. Bold values indicate the best performances.

Drug	Correlation			MAE		
	RF	FRFL	FRF	RF	FRFL	FRF
Model parameters: #Tree = 150, $m = 10$, minimum leaf size = 10						
Erlotinib	0.4408	0.4498	**0.4641**	0.0546	0.0541	**0.0464**
Nilotinib	0.3886	0.4318	**0.4564**	0.0465	0.0464	**0.0376**
PD-0325901	0.4716	0.5057	**0.5658**	0.1353	**0.1335**	0.1377
PLX-4720	0.2957	0.3137	**0.4365**	0.0494	0.0487	**0.0396**
TAE-684	0.2757	0.3385	**0.3743**	0.0728	0.0717	**0.0684**
Model parameters: #Tree = 500, $m = 50$, minimum leaf size = 5						
Erlotinib	0.4381	0.4420	**0.4701**	0.0563	0.0557	**0.0474**
Nilotinib	0.4216	**0.4393**	0.4288	0.0470	0.0471	**0.0391**
PD-0325901	0.5928	0.5929	**0.6381**	0.1287	**0.1282**	0.1322
PLX-4720	0.3738	0.4195	**0.5352**	0.0492	0.0480	**0.0393**
TAE-684	0.3645	0.3888	**0.4211**	0.0711	0.0708	**0.0679**

Table 2. Comparison of predictive performance for AUC from three different approaches: RF, FRFL and FRF with two different model constructions using CCLE data. For FRFL and FRF, node cost is calculated using 8 dose regions. Bold values indicate the best performances.

Drug	Correlation					MAE				
		KL divergence		Hellinger Distance			KL divergence		Hellinger Distance	
	RF	FRFL	FRF	FRFL	FRF	RF	FRFL	FRF	FRFL	FRF
Erlotinib	0.4408	0.4473	0.4620	0.4265	**0.4643**	0.0546	0.0544	**0.0466**	0.0552	0.0472
Nilotinib	0.3886	0.4263	0.4601	0.4475	**0.5009**	0.0465	0.0459	0.0375	0.0457	**0.0373**
PD-0325901	0.4716	0.5149	**0.5775**	0.4920	0.5633	0.1353	**0.1330**	0.1370	0.1352	0.1386
PLX-4720	0.2957	0.3168	0.4308	0.3314	**0.4491**	0.0494	0.0489	0.0398	0.0492	**0.0397**
TAE-684	0.2757	0.3245	**0.3689**	0.2860	0.3337	0.0728	0.0723	**0.0688**	0.0730	0.0697

Table 3. Comparison of predictive performance for AUC from three different approaches: RF, FRFL and FRF using CCLE data. For FRFL and FRF, node cost is calculated using f-divergences (KL divergence or Hellinger distance) of the response distributions at 8 different doses. Bold values indicate the best performances.

evaluation only and generates the prediction using the conventional means of averaging of a specific summary metric (*e.g.*, IC_{50} or *AUC*) stored at the leaf node. All the results are reported for 5 fold cross-validation with 150 trees in each model along with 10 features for node splitting ($m = 10$) and minimum leaf size of 10. We note that both functional approaches (*i.e.*, FRFL and FRF) perform better than the regular RF model for all the presented scenarios. We also compare the results with a different set of parameters which also support the previous conclusion that both FRFL and FRF perform better than the RF. Figure 5(b) shows a representative example of both FRF and RF prediction. Note that we are demonstrating a case where the responses are changing gradually for different doses. Although the performances of both FRF and RF were not stellar in general, the FRF prediction still outperforms RF prediction, especially for higher doses.

Note that Table 3 considers the dose-responses as probability distributions generated based on the mean and standard deviation (SD) of the responses provided by CCLE. We have fitted a Gaussian distribution using the provided mean and SD of responses for each dose point. The mean distribution at a node is calculated using a mixture of Gaussian distribution assumption. Note that the results in both Tables 2 and 3 provide measures for only 5 representative drugs. Table S1 provides the results for all 24 CCLE drugs.

Both Tables 2 and 3 show the performance measures for 5 fold cross-validation. To demonstrate the robustness of our FRF model compared to RF, we also perform our analysis using bootstrap samples of CCLE data. Considering the total number of samples available for each drug, we extract 50 bootstrap sets of samples to build individual FRF and RF models for each set and then perform sensitivity prediction using the built models. Figure 6 illustrates the distributions of differences between MAE values for FRF and RF model predictions against the number of bootstrap samples for four representative drugs (Fig. S2 provides these distributions for all 24 CCLE drugs). For majority of the sets, MAE of FRF is lower than that of RF yielding negative values in x-coordinate. These distributions clearly demonstrate the superior predictive performance and robustness of FRF as compared to a standard RF. Additionally, Table 4 compares the performance of FRF with that of an MRF model, which also demonstrates the overall superior performance of FRF over MRF for the 8 dose points.

Application on GDSC dataset. To demonstrate the versatility of FRF model performance as compared to a traditional RF model, we performed the predictive analysis using another publicly available larger database GDSC. Instead of dose-response points, GDSC v5 provides 105 different *IC* points for dose-response values, extracted from response curves fitted with sigmoidal functions[5] and extrapolated to reach 100% cellular viability. This extrapolation causes the dose values for IC_{90} or IC_{100} to be very high and therefore, we consider only the *IC* values



Figure 6. Distributions of MAE differences between FRF and RF predictions for the 50 bootstrap sets using CCLE data.

Drug	Model	Correlation								
		Dose 1	Dose 2	Dose 3	Dose 4	Dose 5	Dose 6	Dose 7	Dose 8	Mean
Erlotinib	MRF	0.0293	**0.2014**	0.1877	0.2901	0.3915	0.4813	0.4942	0.4071	0.3103
	FRF	**0.0662**	0.1781	**0.2138**	**0.3256**	**0.4378**	**0.4955**	**0.5094**	**0.4100**	**0.3296**
Nilotinib	MRF	−0.0725	**0.1966**	0.1550	0.2860	0.3734	0.4255	0.3888	0.1830	0.2420
	FRF	**−0.0776**	0.1360	**0.2186**	**0.3306**	**0.4182**	**0.4546**	**0.4310**	**0.2502**	**0.2702**
PD-0325901	MRF	0.1402	0.3722	0.4842	0.5395	0.5776	0.5871	0.5668	0.5181	0.4732
	FRF	**0.2013**	**0.4397**	**0.5239**	**0.5798**	**0.6067**	**0.6078**	**0.5952**	**0.5426**	**0.5121**
PLX-4720	MRF	**−0.0522**	−0.0137	0.0885	0.1818	0.3986	0.4682	**0.5018**	0.3732	0.2433
	FRF	−0.0045	**0.1297**	**0.1259**	**0.2434**	**0.4028**	**0.4779**	0.4973	**0.3772**	**0.2812**
TAE-684	MRF	**0.1068**	0.1485	0.0045	0.1509	0.3236	0.3448	0.2914	0.2874	0.2072
	FRF	0.0978	**0.1615**	**0.0541**	**0.2358**	**0.3654**	**0.3867**	**0.3736**	**0.3008**	**0.2470**

Table 4. Comparison of predictive performances of FRF and MRF for 8 different dose points using CCLE data. All the models are built using 150 trees, $m = 10$ node splitting features and minimum leaf size of 10.

Drug	Model	MAE									
		AUC	IC_{10}	IC_{20}	IC_{30}	IC_{40}	IC_{50}	IC_{60}	IC_{70}	IC_{80}	Mean
Erlotinib	RF	0.0596	2.0831	1.7472	1.5039	1.3291	1.1948	1.0692	1.0133	1.0304	1.3714
	FRF	**0.0486**	**1.9813**	**1.6597**	**1.4382**	**1.2694**	**1.1357**	**1.0361**	**0.9867**	**1.0095**	**1.3146**
Rapamycin	RF	0.0640	**4.3771**	3.4771	2.9370	2.5294	2.2000	2.0355	2.0207	2.5359	2.7641
	FRF	**0.0636**	4.3905	**3.4525**	**2.8895**	**2.4642**	**2.1379**	**1.9446**	**2.0046**	**2.4707**	**2.7193**
Sunitinib	RF	0.0963	1.5494	1.5297	1.5542	1.6105	1.6518	1.7013	1.7750	1.8728	1.6556
	FRF	**0.0902**	**1.5306**	**1.5119**	**1.5378**	**1.5750**	**1.6276**	**1.6812**	**1.7428**	**1.8372**	**1.6305**
PHA-665752	RF	0.0370	1.4403	1.2665	1.1492	1.0658	1.0002	0.9555	0.9539	0.9485	1.0975
	FRF	**0.0259**	**1.3522**	**1.2051**	**1.0999**	**1.0149**	**0.9546**	**0.9054**	**0.8954**	**0.9097**	**1.0422**
MG-132	RF	0.1246	1.6207	1.6688	1.7445	1.7830	1.8549	1.9289	2.0313	2.1509	1.8479
	FRF	**0.1070**	**1.6062**	**1.6479**	**1.6968**	**1.7541**	**1.8117**	**1.8794**	**1.9619**	**2.0857**	**1.8055**

Table 5. Comparison of predictive performance on GDSC dataset for multiple drug sensitivity measures (*AUC* and 8 *IC* values) using both RF and FRF. For FRF, node cost is calculated using 8 different *IC* regions. Bold values indicate the best performance.

indicating $\leq$80% viability in our models. We design a single FRF model to predict the complete dose-response curve from IC_1 to IC_{80} and thereafter, the *AUC*. However, RF is unable to replicate this procedure and therefore, we design 8 separate models to predict 8 different *IC* values in an interval of 10 (*i.e.*, IC_{10}, IC_{20}, …, IC_{80}) and one additional model to predict the *AUC*. Table 5 provides the MAE values measured at the 8/*IC* points and *AUC* for both FRF and RF for 5 representative drugs (Table S2 provides the performance comparison for all 140 GDSC (v5) drugs). For all 5 drugs, FRF displays a superior performance in predicting different *IC* and *AUC* values as compared to RF. These results demonstrate the higher efficacy of FRF in the larger context of drug sensitivity prediction for various dose or response points.



Figure 7. Difference between MAEs of FRF and RF for (i) Mean *IC* values, and (ii) *AUC* values for 70 drugs from GDSC.



Figure 8. Data extraction procedure for Functional Regression Tree model. From each of the 21 observed protein expression curves, we calculate the *AUC*, IC_{25}, IC_{50} and IC_{75} values resulting in a complete feature matrix of 21×4. For response modeling, the entire cellular viability curve post drug application is used directly.

Figure 7 illustrates the difference between MAE values of FRF and RF predictions for Mean *IC* and *AUC* values for 70 drugs from GDSC. For mean *IC*, FRF shows superior performance in 68 out of 70 applied drugs, while FRF outperforms RF in 58 out of 70 applied drugs for *AUC* prediction. These results support the conclusion achieved from CCLE data analysis that FRF provides higher predictive accuracy than a regular RF. Figure S3 provides the performance comparison of the rest of the 140 GDSC (v5) drugs.

Function-to-function regression using HMS-LINCS. As described earlier, the HMS-LINCS database provides functional data for input proteomic expressions (for 21 proteins) and output cellular viability[16,17] post application of 5 different drugs at 7 different doses in 10 melanoma cell lines at multiple time points. For our analysis, we only use the 48-hour data since it contains complete records for both input and output. Thus, we have 50 samples in total with 143 predictors (*i.e.*, $21 \times 7 - 4 = 143$, since we exclude 4 proteins due to missing values). The detailed description of the data extraction framework is provided in section Function-to-function regression with FRF with a pictorial representation in Fig. 8. For our function-to-function regression using FRF, we either consider the 143 predictors directly as input features, or extract the 3rd degree polynomial-fitted dose-expression curve features to use as predictors. As the curve features, we estimate 3 different *IC* points at IC_{25}, IC_{50} and IC_{75} and the overall *AUC*, as shown in Figs 3 & S1 for all 21 proteins. Table 6 displays the function-to-function regression results for 3 different input scenarios using FRF. We compare these performances with the performances of dose-wise standard RF models using the 143 expression values as input features for the 50 samples. From Table 6, we observe that FRF provides superior performance as compared to RF for all 3 scenarios while the usage of curve *IC* features provides the highest reduction (~20%) in prediction error. These results clearly demonstrate the potential of FRF in enhancing the predictive modeling performance *via* utilizing the functional input curve features.

Model	Input Feature Description	#Features	#Models	MAE
RF	Protein Expression	143	7	0.2656
FRF	Protein Expression	143	1	0.2602
	AUC, IC_{25}, IC_{50} & IC_{75} of dose-expression curve	84	1	0.2255
	IC_{25}, IC_{50} & IC_{75} of dose-expression curve	63	1	**0.2154**

Table 6. Comparison of predictive performance of RF and FRF with functional data input from HMS-LINCS where *AUC*, IC_{25}, IC_{50} & IC_{75} values of proteomic dose-expression curves are used as input features. Bold value indicates the best performance.

Drug	Model	#Nodes	#Edges	Expected #edges	Ratio of observed to expected #edges	PPI enrichment *p*-value
Erlotinib	RF	107	132	127	1.04	0.356
	FRF	105	170	142	**1.20**	**0.013**
Nilotinib	RF	102	185	162	1.14	0.044
	FRF	101	173	144	**1.20**	**0.010**
PD-0325901	RF	107	191	187	1.02	0.407
	FRF	113	153	139	**1.10**	**0.134**
PLX-4720	RF	106	159	147	1.08	0.164
	FRF	111	217	187	**1.16**	**0.018**
TAE-684	RF	103	159	141	1.13	0.078
	FRF	106	180	151	**1.19**	**0.011**

Table 7. Protein-protein interaction enrichment analysis for top 200 genes picked from RF and FRF using the whole genome statistical background with a minimum interaction score of 0.15.

Biological validation of the models. A potential model validation approach is to consider the *variable importance measure* (VIM) of the genes. We expect that a better model will have higher feature scores for the significant genes, and thus, in turn will result in a higher biological relevance. Typically in RF based models, VIM (or feature score) is calculated from either the frequency of feature selection, out of bag errors, or permutation measures[24,25]. In this section, we use the frequency based approach to calculate the VIM score from the number of times a gene is considered and the number of times it actually gets selected in splitting the nodes.

$$\text{VIM}_j = \frac{\#\text{times gene } j \text{ is selected}}{\#\text{times gene } j \text{ is considered}} = \frac{m_j^{\text{selected}}}{m_j^{\text{picked}}} \tag{18}$$

For our FRF models, we have selected the parameters values as #Trees = 500, $m = 50$, minimum leaf size = 5 for a 5 fold cross-validation of CCLE data. Based on these values, all 18,405 CCLE genes gets picked around 600 to 900 times, giving each a fair chance to contribute to the model. The top features of the models (*i.e.*, genes with higher VIM scores) are then biologically validated in terms of protein-protein interaction (PPI) network enrichment analysis.

There are a number of Bioinformatics resources (*e.g.*, STRING[26], GeneMANIA, DAVID etc.) available for evaluation of the number of observed PPIs in a set of selected genes. These interactions have been determined using prior knowledge and information from various interaction sources such as literature text-mining, experiment results, genomic/proteomic databases, gene co-expressions, gene neighborhood, gene fusion and co-occurrences. For CCLE, we have used Affymetrix HG-U133A mapping to convert the top features into corresponding genes. These genes are then provided as the inputs in the STRING database (http://string-db.org/) to extract the known PPI network. Table 7 shows the PPI analysis results for entire genome with a minimum interaction score of 0.15 for the 5 previously considered drugs for both FRF and equivalent RF models. We observe a higher level of connectivity enrichment for the top 200 FRF features as compared to the top 200 RF features in terms of PPI enrichment *p*-value and the ratio of observed to expected number of edges[27], resulting from possibly the functional collaborations between the products of the FRF genes.

Discussion

In this article, we have presented an enhancement to Random Forest modeling that can incorporate both stationary and functional inputs to predict functional output. The ability to predict the complete functional dose-response profile can be instrumental in various scenarios. For instance, there can be multiple dose-response curves with similar values of the extracted features (*i.e.*, *AUC* or IC_{50}) but they can significantly differ in cytotoxicity or cell viability rate at higher doses. Figure 9 shows an example of this phenomenon where two different dose-response curves for two distinct cell lines in CCLE after AZD-6244 administration have almost the same *AUC* values ($AUC_1 = 0.0945$, $AUC_2 = 0.095$) but different rates of cell viability change at doses $\geq 0.25\,\mu M$. Figure 9 also demonstrates that FRF is capable of capturing the different response curve behaviors for the two cell lines.



Figure 9. Illustration of different dose-response curves for two cell lines in CCLE post AZD-6244 application with similar AUC values but different responses at higher doses. The complete dose-response profile prediction using Functional Random Forest is able to capture the difference in response behaviors for majority of the doses.



Figure 10. Two different dose-response curves with the same IC_{50} and *AUC* values.

Through the application on both synthetic and actual biological data, we have established the superior performance of FRF in predicting dose-response curve summary metrics such as *AUC* and IC_{50} as compared to naïve Random Forest model trained on these metrics as output. Furthermore, FRF predicts the entire dose-response profile incorporating the continuous nature of the curve that separate RF models for individual doses fails to capture. We have illustrated this behavior for GDSC dataset by modeling 8 *IC* points using 8 different RFs to generate the dose-response profile which has an inferior performance compared to the continuous curve prediction from FRF (Table 5). Moreover, a major advantage of predicting a complete curve is the visualization of the changes in response across different doses. Figure 10 shows two representative cases of Curve$^{(1)}$ and Curve$^{(2)}$ that has same IC_{50} values and similar *AUC* values but their dose-response profiles are significantly different. For instance, a small dose increase above IC_{50} will produce significantly higher sensitivity for Curve$^{(1)}$ whereas Curve$^{(2)}$ will have minimal change for dose increases above the IC_{50} value. This behavior will not be captured if we only predict the *AUC* or IC_{50} summary metric as both the curves have similar IC_{50} and *AUC* values. This example illustrates the need for complete dose-response profile prediction in the larger context of drug sensitivity prediction.

There are a number of adjustable parameters available in any regression tree based model (*i.e.*, minimum leaf size, maximum features used for split, and number of trees in the forest) that we can change to get optimal performance, as illustrated in Table 2. Note that increasing the model complexity has similar impact on both RF and FRF models with FRF retaining its superior performance over RF but with a higher computational demand. However, we also observed several drugs in CCLE (e.g., 17-AAG, AZD-6244, Paclitaxel, PD-0325901) for which the prediction errors (MAE) for both FRF and RF are quite high. For these drugs, the dose-response points at different doses for the available cell lines are stretched out and the resulting fitted curves or summary metrics show significant variations which cannot be captured by any Random Forest based model since it employs an smoothing strategy (averaging) in the leaf nodes to provide estimates around the mean prediction. We are currently

looking at different types of regression modeling to solve this issue of bias in prediction. We also hope to further extend this work *via* the incorporation of joint prediction of multiple correlated dose-response profiles while preserving the output dependency structure.

References

1. Barretina, J. *et al.* The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. *Nature* **483**, 603–607 (2012).
2. Costello, J. C. *et al.* A community effort to assess and improve drug sensitivity prediction algorithms. *Nature biotechnology* **32**, 1202–1212 (2014).
3. Wan, Q. & Pal, R. An ensemble based top performing approach for nci-dream drug sensitivity prediction challenge. *PloS one* **9**, e101183 (2014).
4. Pal, R. *Predictive Modeling of Drug Sensitivity* (Academic Press, 2016).
5. Yang, W. *et al.* Genomics of drug sensitivity in cancer (gdsc): a resource for therapeutic biomarker discovery in cancer cells. *Nucleic acids research* **41**, D955–D961 (2013).
6. Seashore-Ludlow, B. *et al.* Harnessing connectivity in a large-scale small-molecule sensitivity dataset. *Cancer discovery* **5**, 1210–1223 (2015).
7. Sirski, M. *On the statistical analysis of functional data arising from designed experiments*. Ph.D. thesis, University of Manitoba (Canada) (2012).
8. Riddick, G. *et al.* Predicting in vitro drug sensitivity using random forests. *Bioinformatics* **27**, 220–224 (2011).
9. Rahman, R., Haider, S., Ghosh, S. & Pal, R. Design of probabilistic random forests with applications to anticancer drug sensitivity prediction. *Cancer informatics* **14**, 57 (2015).
10. Rahman, R., Otridge, J. & Pal, R. Integratedmrf: random forest-based framework for integrating prediction from different data types. *Bioinformatics* (*Oxford*, *England*) (2017).
11. Dhruba, S. R., Rahmanl, R., Matlockl, K., Ghosh, S. & Pal, R. Dimensionality reduction based transfer learning applied to pharmacogenomics databases. In *2018 40th Annual International Conference of the IEEE Engineering in Medicine and Biology Society* (*EMBC*), 1246–1249 (IEEE, 2018).
12. Ramsay, J. O. *Functional data analysis* (Wiley Online Library, 2006).
13. Yu, Y. & Lambert, D. Fitting trees to functional data, with an application to time-of-day patterns. *Journal of Computational and graphical Statistics* **8**, 749–762 (1999).
14. Nerini, D. & Ghattas, B. Classifying densities using functional regression trees: Applications in oceanology. *Computational Statistics & Data Analysis* **51**, 4984–4993 (2007).
15. Rahman, R. & Pal, R. Analyzing drug sensitivity prediction based on dose response curve characteristics. In *Biomedical and Health Informatics* (*BHI*), *2016 IEEE-EMBS International Conference on*, 140–143 (IEEE, 2016).
16. Fallahi-Sichani, M. *et al.* Systematic analysis of brafv600e melanomas reveals a role for jnk/c-jun pathway in adaptive resistance to drug-induced apoptosis. *Molecular Systems Biology* **11**, 797 (2015).
17. Matlock, K., Dhruba, S. R., Nazir, M. & Pal, R. An investigation of proteomic data for application in precision medicine. In *Biomedical & Health Informatics* (*BHI*), *2018 IEEE EMBS International Conference on*, 377–380 (IEEE, 2018).
18. Breiman, L. Random forests. *Machine learning* **45**, 5–32 (2001).
19. Wold, S., Esbensen, K. & Geladi, P. Principal component analysis. *Chemometrics and intelligent laboratory systems* **2**, 37–52 (1987).
20. Meinshausen, N. Quantile regression forests. *Journal of Machine Learning Research* **7**, 983–999 (2006).
21. Biau, G. Analysis of a random forests model. *Journal of Machine Learning Research* **13**, 1063–1095 (2012).
22. Kullback, S. & Leibler, R. A. On information and sufficiency. *The annals of mathematical statistics* **22**, 79–86 (1951).
23. Hellinger, E. Neue begründung der theorie quadratischer formen von unendlichvielen veränderlichen. *Journal für die reine und angewandte Mathematik* **136**, 210–271 (1909).
24. Archer, K. J. & Kimes, R. V. Empirical characterization of random forest variable importance measures. *Computational Statistics & Data Analysis* **52**, 2249–2260 (2008).
25. Haider, S., Rahman, R., Ghosh, S. & Pal, R. A copula based approach for design of multivariate random forests for drug sensitivity prediction. *PloS one* **10**, e0144490 (2015).
26. Szklarczyk, D. *et al.* String v10: protein–protein interaction networks, integrated over the tree of life. *Nucleic acids research* **43**, D447–D452 (2014).
27. Taguchi, Y. Principal components analysis based unsupervised feature extraction applied to gene expression analysis of blood from dengue haemorrhagic fever patients. *Scientific reports* **7**, 44016 (2017).

Acknowledgements

This work has been supported by NIH grant R01GM122084-01.

Author Contributions

R.R., S.G. and R.P. conceived of and designed the experiments. R.R. and S.R.D. performed the experiments. R.R. and R.P. analyzed the data. R.R., S.R.D. and R.P. wrote the paper. All authors have read and approved the final manuscript.

Additional Information

Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-38231-w.

Competing Interests: The authors declare no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary: Functional Random Forest with applications in dose response predictions

Raziur Rahman, Saugato Rahman Dhruba, Souparno Ghosh and Ranadip Pal



Figure S1: Post Drug and DMSO-treated Protein Expression for Drug AZ-628 for Cell Line C32 for p-S6 protein

Table S1: Correlation coefficient and Mean Absolute Error (MAE) between actual and predicted drug sensitivities (AUC) for 3 methods; RF, FRFL and FRF with three different model constructions. In FRFL and FRF, node cost is calculated using 8 dose regions. Here, results of all 24 drugs of CCLE database are shown.

Drug Name	FRF node cost criteria	Correlation Coefficient			Mean Absolute Error		
		RF	FRFL	FRF	RF	FRFL	FRF
17-AAG	Points from 8 dose regions	0.3181	0.338	**0.4213**	0.1009	**0.1002**	0.1108
	Distributions from 8 dose regions (KL divergence)		0.234	0.3317		0.1022	0.1146
	Distributions from 8 dose regions (Hellinger Distance)		0.2962	0.3424		0.1018	0.1144
AZD-0530	Points from 8 dose regions	0.3095	**0.3459**	0.3041	0.0684	0.0676	**0.0618**
	Distributions from 8 dose regions (KL divergence)		0.3127	0.2997		0.0689	0.0622
	Distributions from 8 dose regions (Hellinger Distance)		0.3023	0.2926		0.0692	0.0622
AZD-6244	Points from 8 dose regions	0.4866	0.5242	**0.5716**	0.1009	0.0994	**0.0994**
	Distributions from 8 dose regions (KL divergence)		0.4809	0.5296		0.1015	0.1014
	Distributions from 8 dose regions (Hellinger Distance)		0.4889	0.522		0.1015	0.1016
Lapatinib	Points from 8 dose regions	0.4552	0.4688	0.5052	0.0579	0.0573	0.048
	Distributions from 8 dose regions (KL divergence)		0.4524	0.5056		0.0578	0.0481
	Distributions from 8 dose regions (Hellinger Distance)		0.4633	**0.5285**		0.0578	**0.0474**
Nutlin-3	Points from 8 dose regions	0.0542	**0.124**	0.0648	0.0356	0.0354	**0.0302**
	Distributions from 8 dose regions (KL divergence)		0.0993	0.0519		0.0353	0.0302
	Distributions from 8 dose regions (Hellinger Distance)		0.0796	0.0238		0.0354	0.0304
Paclitaxel	Points from 8 dose regions	0.3934	0.3905	0.4251	0.1215	0.1216	0.1241
	Distributions from 8 dose regions (KL divergence)		0.3773	0.4022		0.1207	0.1236
	Distributions from 8 dose regions (Hellinger Distance)		0.3932	0.4266		0.1209	0.1238
PD-0332991	Points from 8 dose regions	0.4115	0.4394	0.4180	0.0512	0.0503	**0.0459**
	Distributions from 8 dose regions (KL divergence)		0.4226	0.3968		0.0506	0.0463
	Distributions from 8 dose regions (Hellinger Distance)		**0.4445**	0.4127		0.0503	0.0463
PF2341066 /Crizotinib	Points from 8 dose regions	0.2931	**0.3266**	0.3095	0.0459	0.0452	**0.0372**
	Distributions from 8 dose regions (KL divergence)		0.2742	0.2434		0.0462	0.0378
	Distributions from 8 dose regions (Hellinger Distance)		0.2281	0.1755		0.0464	0.0384
PHA-665752	Points from 8 dose regions	0.1695	0.1902	0.1588	0.0469	0.0464	**0.0375**
	Distributions from 8 dose regions (KL divergence)		**0.2031**	0.1898		0.0457	0.0375
	Distributions from 8 dose regions (Hellinger Distance)		0.198	0.1592		0.0457	0.0378
Sorafenib	Points from 8 dose regions	0.3755	**0.3824**	0.3668	0.0384	0.0383	**0.0321**
	Distributions from 8 dose regions (KL divergence)		0.3390	0.3023		0.0391	0.0328
	Distributions from 8 dose regions (Hellinger Distance)		0.3392	0.3143		0.0392	0.0327
AEW541	Points from 8 dose regions	0.2757	0.2619	**0.3073**	0.0545	0.0548	**0.0487**
	Distributions from 8 dose regions (KL divergence)		0.2331	0.2758		0.0554	0.0493

Table S1: Correlation coefficient and Mean Absolute Error (MAE) between actual and predicted drug sensitivities (AUC) for 3 methods; RF, FRFL and FRF with three different model constructions. In FRFL and FRF, node cost is calculated using 8 dose regions. Here, results of all 24 drugs of CCLE database are shown.

Drug Name	FRF node cost criteria	Correlation Coefficient			Mean Absolute Error		
		RF	FRFL	FRF	RF	FRFL	FRF
	Distributions from 8 dose regions (Hellinger Distance)		0.2409	0.2875		0.0553	0.0491
Irinotecan	Points from 8 dose regions	0.519	0.5234	**0.5344**	0.0881	0.0875	0.1021
	Distributions from 8 dose regions (KL divergence)		0.528	0.5321		**0.0872**	0.1021
	Distributions from 8 dose regions (Hellinger Distance)		0.5285	0.5332		0.0883	0.1029
L-685458	Points from 8 dose regions	0.3611	0.3754	**0.4000**	0.0416	0.0412	**0.0295**
	Distributions from 8 dose regions (KL divergence)		0.3571	0.3810		0.0416	0.0302
	Distributions from 8 dose regions (Hellinger Distance)		0.3553	0.3758		0.0417	0.0301
LBW242	Points from 8 dose regions	0.1140	0.1217	**0.1377**	0.0563	0.0556	**0.0517**
	Distributions from 8 dose regions (KL divergence)		0.0662	0.1032		0.0558	0.0526
	Distributions from 8 dose regions (Hellinger Distance)		0.0661	0.1198		0.0562	0.0528
Panobinostat	Points from 8 dose regions	0.5239	0.5335	0.5584	**0.0640**	0.0641	0.0724
	Distributions from 8 dose regions (KL divergence)		0.5101	0.5374		0.0651	0.0739
	Distributions from 8 dose regions (Hellinger Distance)		0.5388	**0.5611**		0.0643	0.0731
RAF265	Points from 8 dose regions	0.3739	0.3992	**0.4149**	0.0687	**0.0684**	0.0716
	Distributions from 8 dose regions (KL divergence)		0.3557	0.3735		0.0690	0.0724
	Distributions from 8 dose regions (Hellinger Distance)		0.3005	0.3123		0.0704	0.0738
TKI258	Points from 8 dose regions	0.3799	**0.3986**	0.3831	0.0512	0.0506	**0.0447**
	Distributions from 8 dose regions (KL divergence)		0.3408	0.3041		0.0521	0.0461
	Distributions from 8 dose regions (Hellinger Distance)		0.3377	0.3261		0.0523	0.0457
Topotecan	Points from 8 dose regions	0.5122	0.5006	0.5297	0.1055	0.1061	0.1161
	Distributions from 8 dose regions (KL divergence)		0.5138	**0.5342**		**0.1053**	0.1158
	Distributions from 8 dose regions (Hellinger Distance)		0.4983	0.5255		0.1069	0.1176
ZD-6474	Points from 8 dose regions	0.2428	0.2696	0.2735	0.0641	0.0634	**0.0581**
	Distributions from 8 dose regions (KL divergence)		0.2602	**0.2842**		0.0634	0.0582
	Distributions from 8 dose regions (Hellinger Distance)		0.185	0.2107		0.0643	0.059

Table S2: Mean Absolute Error (MAE) between actual and predicted drug sensitivities (AUC and different IC's) for 2 methods; RF and FRF. In FRF, node cost is calculated using 8 IC regions. Here, results of all 140 drugs of GDSC database $v5$ are shown.

Drug Name	Model	AUC	IC_{10}	IC_{20}	IC_{30}	IC_{40}	IC_{50}	IC_{60}	IC_{70}	IC_{80}	Average
Erlotinib	RF	0.0596	2.0831	1.7472	1.5039	1.3291	1.1948	1.0692	1.0133	1.0304	1.3714
	FRF	0.0486	1.9813	1.6597	1.4382	1.2694	1.1357	1.0361	0.9867	1.0095	1.3146
Rapamycin	RF	0.064	4.3771	3.4771	2.937	2.5294	2.2	2.0355	2.0207	2.5359	2.7641

Table S2: Mean Absolute Error (MAE) between actual and predicted drug sensitivities (AUC and different IC's) for 2 methods; RF and FRF. In FRF, node cost is calculated using 8 IC regions. Here, results of all 140 drugs of GDSC database $v5$ are shown.

Drug Name	Model	AUC	IC_{10}	IC_{20}	IC_{30}	IC_{40}	IC_{50}	IC_{60}	IC_{70}	IC_{80}	Average
	FRF	0.0636	4.3905	3.4525	2.8895	2.4642	2.1379	1.9446	2.0046	2.4707	2.7193
Sunitinib	RF	0.0963	1.5494	1.5297	1.5542	1.6105	1.6518	1.7013	1.775	1.8728	1.6556
	FRF	0.0902	1.5306	1.5119	1.5378	1.575	1.6276	1.6812	1.7428	1.8372	1.6305
PHA-665752	RF	0.037	1.4403	1.2665	1.1492	1.0658	1.0002	0.9555	0.9539	0.9485	1.0975
	FRF	0.0259	1.3522	1.2051	1.0999	1.0149	0.9546	0.9054	0.8954	0.9097	1.0422
MG-132	RF	0.1246	1.6207	1.6688	1.7445	1.783	1.8549	1.9289	2.0313	2.1509	1.8479
	FRF	0.107	1.6062	1.6479	1.6968	1.7541	1.8117	1.8794	1.9619	2.0857	1.8055
Paclitaxel	RF	0.1427	1.8698	1.8716	1.8982	1.947	1.9976	2.0908	2.1783	2.3253	2.0223
	FRF	0.1435	1.7694	1.763	1.8013	1.8616	1.9243	2.0036	2.1211	2.2762	1.9401
Cyclopamine	RF	0.0315	1.3288	1.2346	1.188	1.1736	1.155	1.1749	1.2055	1.2627	1.2154
	FRF	0.0274	1.34	1.2443	1.1874	1.1624	1.1541	1.1556	1.1646	1.2096	1.2022
AZ628	RF	0.133	2.5134	2.1669	1.9748	1.8824	1.823	1.8044	1.8521	1.9362	1.9942
	FRF	0.1203	2.446	2.1155	1.9411	1.8337	1.7714	1.7544	1.7966	1.8978	1.9446
Sorafenib	RF	0.0766	1.5314	1.4777	1.4452	1.4407	1.4627	1.4575	1.4845	1.532	1.4789
	FRF	0.0662	1.5193	1.4681	1.4438	1.4394	1.4388	1.4417	1.4622	1.5037	1.4646
VX-680	RF	0.128	2.5637	2.3388	2.2608	2.1607	2.1121	2.0611	2.0323	2.0098	2.1924
	FRF	0.12	2.526	2.3258	2.2177	2.1569	2.0957	2.0445	2.0051	1.9705	2.1678
Imatinib	RF	0.0383	1.2762	1.1374	1.07	0.9765	0.9454	0.9043	0.872	0.8502	1.004
	FRF	0.0258	1.1553	1.0502	0.9733	0.9056	0.8562	0.8255	0.8	0.7784	0.9181
NVP-TAE684	RF	0.1156	1.7224	1.6634	1.6829	1.7587	1.8194	1.8944	2.0052	2.1901	1.8421
	FRF	0.111	1.7162	1.656	1.673	1.7253	1.795	1.8872	2.0037	2.1722	1.8286
PF-02341066	RF	0.0475	1.2559	1.1949	1.1595	1.1705	1.1532	1.1884	1.1808	1.1968	1.1875
	FRF	0.0364	1.2281	1.1682	1.1354	1.1268	1.1234	1.125	1.1286	1.1339	1.1462
AZD-0530	RF	0.0661	1.7654	1.6408	1.5783	1.5453	1.5295	1.5384	1.5438	1.5804	1.5902
	FRF	0.0543	1.7413	1.6184	1.5425	1.494	1.4786	1.4608	1.4598	1.4899	1.5357
S-Trityl-L-cysteine	RF	0.0844	1.3216	1.3881	1.4569	1.5297	1.6323	1.7073	1.8311	1.9878	1.6069
	FRF	0.0857	1.2496	1.2909	1.3527	1.4335	1.5304	1.6421	1.7723	1.9423	1.5267
Z-LLNle-CHO	RF	0.0821	1.1943	1.2622	1.3096	1.3575	1.419	1.506	1.5874	1.7042	1.4175
	FRF	0.0776	1.2078	1.2557	1.3103	1.3656	1.4311	1.498	1.5824	1.7033	1.4193
Dasatinib	RF	0.1706	3.5646	3.0769	2.8374	2.7091	2.6161	2.5967	2.6919	2.8865	2.8724
	FRF	0.1533	3.4158	2.8774	2.5761	2.4423	2.3922	2.4175	2.5577	2.8209	2.6875
GNF-2	RF	0.0288	1.1946	1.0841	1.0022	0.9293	0.8772	0.805	0.7644	0.726	0.9229
	FRF	0.0194	1.1075	1.0125	0.9392	0.8756	0.815	0.7561	0.7052	0.6711	0.8603
CGP-60474	RF	0.1135	1.0519	1.1472	1.2349	1.3366	1.4259	1.5384	1.637	1.8148	1.3983
	FRF	0.11	1.037	1.1013	1.176	1.2478	1.3304	1.4262	1.5422	1.6967	1.3197
CGP-082996	RF	0.0499	1.3682	1.2746	1.2494	1.2615	1.2897	1.3178	1.3822	1.4746	1.3273
	FRF	0.0483	1.3642	1.2538	1.2258	1.2308	1.2492	1.2857	1.3428	1.4244	1.2971
A-770041	RF	0.1158	2.3238	2.0588	1.9727	1.9075	1.9085	1.9381	1.9732	2.0792	2.0202
	FRF	0.1057	2.3063	2.0748	1.961	1.8997	1.8858	1.9116	1.9702	2.0925	2.0127
WH-4-023	RF	0.1482	3.4064	2.961	2.6643	2.5482	2.3909	2.325	2.2569	2.2913	2.6055
	FRF	0.1328	3.2713	2.8204	2.5265	2.3121	2.2125	2.153	2.1514	2.2259	2.4591
WZ-1-84	RF	0.0514	1.4484	1.3295	1.2695	1.2642	1.264	1.2992	1.3357	1.3759	1.3233
	FRF	0.0459	1.4604	1.3367	1.2716	1.2381	1.2306	1.2573	1.3035	1.3701	1.3085
BI-2536	RF	0.1117	1.4583	1.5436	1.5907	1.6808	1.7689	1.8626	1.9685	2.1153	1.7486
	FRF	0.1116	1.3783	1.4435	1.5221	1.6042	1.6938	1.7954	1.9141	2.0728	1.678
BMS-536924	RF	0.1267	2.0026	1.8233	1.7752	1.8229	1.8784	1.9658	2.0645	2.2417	1.9468
	FRF	0.1229	1.9668	1.805	1.7773	1.8113	1.8687	1.9507	2.0696	2.2405	1.9362
BMS-509744	RF	0.061	1.1916	1.1434	1.1819	1.2403	1.3262	1.4328	1.5584	1.7181	1.3491
	FRF	0.0598	1.1735	1.1189	1.1543	1.2289	1.3097	1.4059	1.5275	1.6834	1.3253
CMK	RF	0.0542	1.2626	1.2502	1.2695	1.2988	1.3715	1.4291	1.5457	1.6627	1.3863
	FRF	0.052	1.2608	1.2323	1.2579	1.2972	1.3541	1.4314	1.53	1.6566	1.3775
Pyrimethamine	RF	0.1023	1.8621	1.7736	1.7716	1.7731	1.8369	1.8816	1.9761	2.1094	1.8731
	FRF	0.0977	1.8691	1.7703	1.7436	1.7442	1.7803	1.8403	1.927	2.0521	1.8409

Table S2: Mean Absolute Error (MAE) between actual and predicted drug sensitivities (AUC and different IC's) for 2 methods; RF and FRF. In FRF, node cost is calculated using 8 IC regions. Here, results of all 140 drugs of GDSC database $v5$ are shown.

Drug Name	Model	AUC	IC_{10}	IC_{20}	IC_{30}	IC_{40}	IC_{50}	IC_{60}	IC_{70}	IC_{80}	Average
JW-7-52-1	RF	0.1656	1.7563	1.7574	1.8373	1.9039	2.0276	2.1625	2.331	2.6052	2.0476
	FRF	0.1624	1.7331	1.6977	1.7539	1.828	1.9207	2.0476	2.2316	2.5101	1.9654
A-443654	RF	0.1041	1.1877	1.2548	1.3428	1.4252	1.525	1.6264	1.7499	1.9333	1.5056
	FRF	0.1098	1.1481	1.2038	1.2673	1.3345	1.4148	1.5074	1.6219	1.7743	1.409
GW843682X	RF	0.1313	1.4825	1.5624	1.6745	1.8111	1.9213	2.0503	2.2123	2.4399	1.8943
	FRF	0.1282	1.3539	1.4181	1.5279	1.6495	1.7819	1.9227	2.0874	2.305	1.7558
MS-275	RF	0.1071	1.4331	1.3756	1.4381	1.5353	1.6439	1.8035	1.9861	2.2498	1.6832
	FRF	0.1101	1.4131	1.3375	1.3661	1.4284	1.5403	1.687	1.8716	2.1332	1.5971
Parthenolide	RF	0.0292	1.3288	1.3005	1.2851	1.2953	1.3239	1.3206	1.3652	1.4048	1.328
	FRF	0.0252	1.3231	1.2926	1.2821	1.2779	1.2901	1.3136	1.346	1.389	1.3143
KIN001-135	RF	0.0109	0.9776	0.8199	0.7239	0.6385	0.5848	0.5464	0.5196	0.516	0.6658
	FRF	0.0084	0.9109	0.7773	0.6848	0.6167	0.5716	0.5382	0.5178	0.5215	0.6424
TGX221	RF	0.0423	2.1298	1.7658	1.5722	1.409	1.2886	1.206	1.1504	1.1496	1.4589
	FRF	0.0373	2.0421	1.7232	1.499	1.3511	1.2383	1.1534	1.1117	1.1188	1.4047
Bortezomib	RF	0.1612	1.1812	1.2946	1.4282	1.551	1.6545	1.7758	1.9099	2.0991	1.6118
	FRF	0.1573	1.1741	1.2949	1.4047	1.5082	1.6134	1.7261	1.8537	2.0156	1.5738
XMD8-85	RF	0.061	1.2746	1.2539	1.2722	1.3208	1.3816	1.4359	1.5091	1.6198	1.3835
	FRF	0.0612	1.2595	1.2201	1.2349	1.2819	1.3317	1.3892	1.4667	1.5738	1.3447
Roscovitine	RF	0.0323	1.2444	1.2559	1.2824	1.3096	1.3652	1.4049	1.4788	1.5651	1.3633
	FRF	0.0359	1.2161	1.2168	1.2533	1.2978	1.3431	1.3985	1.4652	1.5597	1.3438
Salubrinal	RF	0.0412	1.1609	1.1683	1.2238	1.2452	1.3132	1.3688	1.4493	1.5688	1.3123
	FRF	0.0453	1.1214	1.0955	1.141	1.1998	1.2623	1.3363	1.4309	1.5557	1.2679
Lapatinib	RF	0.035	1.6051	1.438	1.3449	1.2572	1.1899	1.1476	1.1089	1.098	1.2737
	FRF	0.0286	1.5788	1.4157	1.3059	1.2172	1.143	1.089	1.0585	1.0568	1.2331
GSK269962A	RF	0.0607	2.4652	2.0184	1.8144	1.6904	1.65	1.6292	1.7006	1.8324	1.8501
	FRF	0.0605	2.4226	1.9997	1.7799	1.6436	1.6047	1.6241	1.6956	1.8423	1.8266
Doxorubicin	RF	0.146	1.5127	1.464	1.431	1.4189	1.4387	1.4453	1.4883	1.5702	1.4712
	FRF	0.1482	1.5085	1.4499	1.4216	1.4113	1.4209	1.4414	1.4862	1.5749	1.4643
Etoposide	RF	0.145	1.8283	1.7765	1.7773	1.7961	1.8403	1.8841	1.9478	2.0716	1.8653
	FRF	0.1431	1.8283	1.7641	1.7639	1.782	1.8172	1.8627	1.9266	2.0524	1.8496
Gemcitabine	RF	0.1459	3.9367	3.4848	3.2466	3.0895	3.0124	2.9827	2.9557	3.0874	3.2245
	FRF	0.2146	3.896	3.4867	3.2414	3.0957	3.0027	2.9604	2.9728	3.0809	3.2171
Mitomycin C	RF	0.1171	1.9372	1.7892	1.7216	1.6468	1.5763	1.5434	1.4947	1.4565	1.6457
	FRF	0.166	1.9319	1.7791	1.6884	1.6264	1.5792	1.5401	1.5012	1.4665	1.6391
Vinorelbine	RF	0.1313	1.3498	1.3781	1.4062	1.4723	1.5399	1.6081	1.7286	1.8578	1.5426
	FRF	0.1311	1.339	1.3442	1.3768	1.4235	1.4918	1.575	1.6774	1.8263	1.5067
NSC-87877	RF	0.0182	0.9975	0.9346	0.9005	0.8663	0.8418	0.8251	0.8191	0.8005	0.8732
	FRF	0.0143	0.9655	0.8984	0.8544	0.8233	0.7978	0.7762	0.7607	0.7475	0.828
Bicalutamide	RF	0.0043	0.5256	0.4937	0.4716	0.448	0.4318	0.4067	0.3866	0.3649	0.4411
	FRF	0.0034	0.5043	0.4732	0.4495	0.429	0.4099	0.3916	0.372	0.3497	0.4224
QS11	RF	0.0659	1.5704	1.5348	1.5367	1.5418	1.5611	1.5827	1.6017	1.6525	1.5727
	FRF	0.0657	1.5393	1.5121	1.5097	1.5186	1.5372	1.562	1.5936	1.641	1.5517
Midostaurin	RF	0.059	1.3132	1.3397	1.3573	1.3883	1.4276	1.4713	1.5155	1.594	1.4259
	FRF	0.0579	1.2857	1.3034	1.3379	1.3728	1.4107	1.4553	1.5075	1.5754	1.4061
CHIR-99021	RF	0.0275	1.3387	1.2564	1.1942	1.1607	1.1124	1.0686	1.0328	0.9916	1.1444
	FRF	0.0214	1.2826	1.2084	1.1523	1.104	1.0614	1.0224	0.9842	0.9374	1.0941
AP-24534	RF	0.0598	1.8811	1.7809	1.7523	1.7353	1.734	1.7353	1.7346	1.7877	1.7677
	FRF	0.0533	1.8183	1.7588	1.7281	1.7159	1.7161	1.7172	1.7198	1.7526	1.7409
AZD6482	RF	0.0638	1.9669	1.706	1.5726	1.4941	1.4239	1.3791	1.3598	1.3879	1.5363
	FRF	0.062	1.9497	1.7093	1.5707	1.4812	1.419	1.3785	1.3618	1.3913	1.5327
JNK-9L	RF	0.1081	0.9043	0.8835	0.8868	0.9125	0.9576	1.0019	1.0787	1.1741	0.9749
	FRF	0.1117	0.9105	0.8647	0.8666	0.8872	0.9211	0.965	1.0291	1.1202	0.9456
PF-562271	RF	0.0412	1.2589	1.209	1.1953	1.1869	1.2109	1.2469	1.2855	1.3578	1.2439

Table S2: Mean Absolute Error (MAE) between actual and predicted drug sensitivities (AUC and different IC's) for 2 methods; RF and FRF. In FRF, node cost is calculated using 8 IC regions. Here, results of all 140 drugs of GDSC database $v5$ are shown.

Drug Name	Model	AUC	IC_{10}	IC_{20}	IC_{30}	IC_{40}	IC_{50}	IC_{60}	IC_{70}	IC_{80}	Average
	FRF	0.0424	1.2454	1.1901	1.1721	1.1719	1.1927	1.2285	1.2812	1.356	1.2297
DMOG	RF	0.1312	1.282	1.2228	1.2297	1.2427	1.2814	1.3371	1.4255	1.5572	1.3223
	FRF	0.133	1.3027	1.2391	1.2319	1.2473	1.2736	1.323	1.4053	1.5426	1.3207
FTI-277	RF	0.017	0.9804	0.9174	0.8753	0.838	0.8089	0.7695	0.7407	0.721	0.8314
	FRF	0.0145	0.9717	0.9137	0.8681	0.8288	0.7917	0.7599	0.7315	0.701	0.8208
OSU-03012	RF	0.1211	1.5365	1.5877	1.6314	1.6724	1.7218	1.774	1.8417	1.9437	1.7136
	FRF	0.1179	1.4924	1.5354	1.5826	1.6361	1.6905	1.7535	1.8317	1.9336	1.682
Shikonin	RF	0.1557	1.2026	1.2308	1.2686	1.312	1.3616	1.3992	1.4636	1.5541	1.3491
	FRF	0.1529	1.1958	1.2223	1.247	1.2749	1.3038	1.3369	1.3785	1.4357	1.2994
AKT inhibitor VIII	RF	0.0424	1.44	1.345	1.2913	1.2431	1.2194	1.1865	1.1679	1.1553	1.2561
	FRF	0.0417	1.453	1.3522	1.2966	1.2561	1.2208	1.1905	1.1667	1.1553	1.2614
Embelin	RF	0.0798	0.8046	0.8379	0.8703	0.9357	0.9864	1.0594	1.1543	1.2867	0.9919
	FRF	0.0834	0.7968	0.8114	0.8484	0.8979	0.9553	1.0227	1.1102	1.2364	0.9599
FH535	RF	0.0993	1.0428	0.951	0.9502	0.9915	1.0625	1.1634	1.3185	1.519	1.1249
	FRF	0.1035	1.041	0.9551	0.9405	0.976	1.043	1.1383	1.2634	1.4528	1.1012
PAC-1	RF	0.0419	1.279	1.2928	1.3061	1.3224	1.3504	1.3731	1.4113	1.4787	1.3517
	FRF	0.0374	1.2726	1.2758	1.2896	1.3037	1.3209	1.3453	1.3737	1.4199	1.3252
IPA-3	RF	0.0718	1.4249	1.493	1.5406	1.5882	1.633	1.6929	1.7499	1.8335	1.6195
	FRF	0.062	1.4351	1.4978	1.5429	1.5839	1.6248	1.6678	1.7185	1.7867	1.6072
GSK-650394	RF	0.083	1.9389	1.8127	1.7379	1.6825	1.6365	1.6407	1.6421	1.6717	1.7204
	FRF	0.0821	1.9194	1.7913	1.7168	1.6742	1.6502	1.643	1.652	1.6793	1.7158
BAY 61-3606	RF	0.0847	1.4156	1.3745	1.3676	1.3639	1.3851	1.4141	1.4754	1.5352	1.4164
	FRF	0.084	1.3702	1.3379	1.3305	1.3458	1.3714	1.4056	1.4533	1.5239	1.3923
Thapsigargin	RF	0.1443	2.4606	2.2228	2.125	2.1017	2.1009	2.1735	2.3333	2.5558	2.2592
	FRF	0.2006	2.4415	2.2248	2.1392	2.099	2.1106	2.167	2.2942	2.5073	2.2479
Obatoclax Mesylate	RF	0.1403	2.1192	1.8568	1.726	1.6432	1.6261	1.6296	1.6731	1.7857	1.7575
	FRF	0.1898	2.0813	1.8454	1.7201	1.6484	1.6151	1.6267	1.6781	1.7878	1.7503
BMS-754807	RF	0.095	2.2446	1.9272	1.7603	1.6571	1.6255	1.6202	1.6669	1.7564	1.7823
	FRF	0.0949	2.1717	1.9078	1.7596	1.6652	1.613	1.6063	1.6544	1.7682	1.7683
OSI-906	RF	0.0694	2.1853	1.9067	1.7479	1.6237	1.5188	1.4414	1.341	1.3061	1.6339
	FRF	0.0644	2.166	1.9151	1.7471	1.6167	1.5058	1.4085	1.3314	1.2881	1.6223
Bexarotene	RF	0.0379	1.6856	1.4569	1.3395	1.2513	1.1976	1.2045	1.2582	1.3605	1.3443
	FRF	0.0384	1.6478	1.4519	1.337	1.2485	1.2035	1.2111	1.2655	1.3683	1.3417
Bleomycin	RF	0.1465	2.8279	2.6156	2.485	2.4248	2.3984	2.4	2.4083	2.5034	2.5079
	FRF	0.1869	2.7953	2.5831	2.4724	2.4019	2.371	2.3788	2.4123	2.5022	2.4896
LFM-A13	RF	0.0202	1.1245	0.9644	0.8699	0.804	0.758	0.7283	0.7126	0.7228	0.8356
	FRF	0.0184	1.1058	0.9607	0.8679	0.8057	0.7607	0.7251	0.7052	0.7068	0.8298
AUY922	RF	0.1312	1.1848	1.2117	1.2561	1.2907	1.3405	1.3907	1.4608	1.5617	1.3371
	FRF	0.1297	1.1737	1.1872	1.2198	1.2552	1.2975	1.3482	1.4148	1.5174	1.3017
Bryostatin 1	RF	0.0241	1.2331	1.1275	1.0628	0.9986	0.9394	0.888	0.8339	0.7944	0.9847
	FRF	0.0204	1.215	1.1204	1.0495	0.9872	0.9293	0.873	0.8234	0.7719	0.9712
Pazopanib	RF	0.0561	1.5966	1.4852	1.4074	1.3737	1.3422	1.3316	1.3162	1.3093	1.3953
	FRF	0.0534	1.5933	1.4671	1.4006	1.3512	1.3164	1.2917	1.2792	1.2772	1.3721
LAQ824	RF	0.1171	1.0134	0.9509	0.9358	0.9405	0.9547	0.984	1.0351	1.1238	0.9923
	FRF	0.119	1.0096	0.9521	0.9311	0.9295	0.9428	0.9638	1.0025	1.0748	0.9758
Epothilone B	RF	0.1433	1.6792	1.636	1.6373	1.659	1.7077	1.737	1.812	1.9295	1.7247
	FRF	0.1451	1.676	1.6324	1.6309	1.6429	1.6752	1.7219	1.7882	1.904	1.7089
GSK-1904529A	RF	0.014	0.9711	0.9024	0.855	0.8122	0.7676	0.7378	0.6971	0.6607	0.8005
	FRF	0.0116	0.9495	0.8884	0.8393	0.7958	0.7546	0.7192	0.6828	0.6416	0.7839
Tipifarnib	RF	0.1036	2.2791	1.8959	1.7326	1.6667	1.657	1.7012	1.8276	2.0671	1.8534
	FRF	0.1211	2.2918	1.9192	1.7418	1.6617	1.6534	1.698	1.8189	2.0461	1.8539
AS601245	RF	0.0666	1.3894	1.3622	1.383	1.3969	1.4299	1.4694	1.5341	1.6179	1.4478
	FRF	0.0666	1.36	1.3358	1.3415	1.363	1.3979	1.4462	1.5136	1.6098	1.421

Table S2: Mean Absolute Error (MAE) between actual and predicted drug sensitivities (AUC and different IC's) for 2 methods; RF and FRF. In FRF, node cost is calculated using 8 IC regions. Here, results of all 140 drugs of GDSC database $v5$ are shown.

Drug Name	Model	AUC	IC_{10}	IC_{20}	IC_{30}	IC_{40}	IC_{50}	IC_{60}	IC_{70}	IC_{80}	Average
AICAR	RF	0.0639	1.0269	1.0315	1.0612	1.0972	1.1428	1.1881	1.2393	1.3417	1.1411
	FRF	0.0668	1.032	1.0296	1.0486	1.077	1.1155	1.1654	1.2304	1.3265	1.1281
Camptothecin	RF	0.1269	1.5973	1.5151	1.5145	1.5219	1.5673	1.6265	1.6957	1.8158	1.6067
	FRF	NaN	1.6203	1.5256	1.5084	1.5273	1.5692	1.6261	1.7031	1.8225	1.6128
Vinblastine	RF	0.1117	1.3215	1.2419	1.2199	1.2175	1.2354	1.2892	1.3667	1.4953	1.2984
	FRF	0.12	1.3417	1.2558	1.2267	1.2257	1.2415	1.2834	1.3566	1.4724	1.3005
Cisplatin	RF	0.0592	1.1523	1.1402	1.1525	1.1805	1.2153	1.255	1.3148	1.3796	1.2238
	FRF	0.0607	1.1455	1.1276	1.1393	1.1709	1.2068	1.2511	1.3039	1.3755	1.2151
Cytarabine	RF	0.0991	1.7843	1.6124	1.5181	1.4816	1.4744	1.5027	1.5626	1.6881	1.578
	FRF	0.1005	1.7876	1.61	1.5156	1.4714	1.4611	1.4841	1.5435	1.6621	1.5669
Docetaxel	RF	0.0952	1.4072	1.333	1.295	1.2839	1.2871	1.3209	1.3588	1.4814	1.3459
	FRF	0.0963	1.4254	1.3339	1.2861	1.2713	1.2738	1.3038	1.3626	1.4675	1.3406
Methotrexate	RF	0.0677	1.6933	1.6202	1.5865	1.5476	1.5207	1.4989	1.4832	1.4829	1.5542
	FRF	0.0582	1.6171	1.5491	1.5046	1.4724	1.4463	1.4331	1.4225	1.418	1.4829
ATRA	RF	0.0403	2.1161	1.7504	1.5301	1.3344	1.1747	1.0602	1.0062	1.0221	1.3743
	FRF	0.0372	1.9996	1.6972	1.49	1.3105	1.1537	1.0337	0.9826	1.0161	1.3354
Gefitinib	RF	0.0314	1.3019	1.1917	1.1168	1.0529	0.9942	0.9415	0.8987	0.8856	1.0479
	FRF	0.0262	1.2569	1.1625	1.0939	1.0359	0.9824	0.9296	0.8841	0.8653	1.0263
ABT-263	RF	0.087	1.752	1.6846	1.6421	1.6277	1.6268	1.6465	1.6753	1.7377	1.6741
	FRF	0.081	1.7347	1.6664	1.6356	1.6158	1.6015	1.6059	1.6261	1.6819	1.646
Vorinostat	RF	0.0868	0.7416	0.7226	0.7217	0.7418	0.7701	0.8043	0.8558	0.9407	0.7873
	FRF	0.0938	0.7441	0.7183	0.7217	0.7374	0.7612	0.7935	0.8382	0.9116	0.7782
Nilotinib	RF	0.0272	1.2416	1.2039	1.176	1.1554	1.1211	1.0933	1.0651	1.0384	1.1369
	FRF	0.0214	1.1982	1.1573	1.1257	1.0969	1.0686	1.0399	1.0093	0.9726	1.0835
RDEA119	RF	0.0915	2.0818	1.8439	1.7375	1.6584	1.6133	1.5826	1.5932	1.6336	1.718
	FRF	0.0872	2.0382	1.8271	1.6984	1.6085	1.5616	1.5375	1.5337	1.5507	1.6694
CI-1040	RF	0.0801	1.7216	1.5116	1.3926	1.3309	1.2916	1.2795	1.3112	1.3987	1.4047
	FRF	0.0791	1.6772	1.4861	1.3904	1.3296	1.2948	1.2845	1.313	1.3826	1.3948
Temsirolimus	RF	0.0605	3.107	2.4579	2.0394	1.7022	1.4974	1.4061	1.4458	1.6783	1.9168
	FRF	0.1137	3.0387	2.3981	1.9973	1.7073	1.5012	1.4104	1.4452	1.6829	1.8976
AZD-2281	RF	0.028	1.1966	1.1539	1.1184	1.0839	1.07	1.0567	1.036	1.0143	1.0912
	FRF	0.023	1.1603	1.1175	1.0858	1.0572	1.0343	1.0155	0.9952	0.9727	1.0548
ABT-888	RF	0.0144	0.9447	0.8848	0.8447	0.7993	0.7594	0.719	0.685	0.6296	0.7833
	FRF	0.0114	0.8949	0.8407	0.7989	0.7613	0.7255	0.6888	0.6488	0.6016	0.7451
Bosutinib	RF	0.0608	1.588	1.5523	1.5198	1.506	1.4876	1.4802	1.4847	1.4832	1.5127
	FRF	0.0567	1.5754	1.5287	1.5083	1.4951	1.4841	1.4743	1.4678	1.4686	1.5003
Lenalidomide	RF	0.016	1.0052	0.9387	0.8897	0.8407	0.8038	0.7576	0.7035	0.6485	0.8235
	FRF	0.0129	0.9652	0.9017	0.8523	0.8085	0.7671	0.7248	0.6783	0.6235	0.7902
Axitinib	RF	0.0435	1.3575	1.3153	1.2879	1.2808	1.2663	1.2524	1.2651	1.2768	1.2878
	FRF	0.0383	1.3407	1.3041	1.2828	1.2651	1.251	1.2418	1.2396	1.2482	1.2717
AZD7762	RF	0.1047	1.2514	1.1954	1.1751	1.1599	1.1632	1.1743	1.2039	1.2718	1.1994
	FRF	0.1076	1.2601	1.2016	1.1752	1.1639	1.158	1.1645	1.1946	1.2555	1.1967
GW 441756	RF	0.0316	1.599	1.3779	1.2191	1.1016	0.9982	0.9177	0.8564	0.8428	1.1141
	FRF	0.026	1.5017	1.3113	1.1758	1.067	0.9759	0.898	0.8428	0.8363	1.0761
CEP-701	RF	0.0924	1.6556	1.4444	1.342	1.2731	1.2387	1.2494	1.303	1.4221	1.366
	FRF	0.1027	1.6428	1.4423	1.3325	1.2636	1.2273	1.2334	1.2889	1.412	1.3553
SB 216763	RF	0.0198	1.0793	1.0495	1.0317	0.9973	0.9823	0.9663	0.9409	0.9195	0.9958
	FRF	0.0164	1.0359	1.0057	0.9814	0.9585	0.9361	0.9129	0.888	0.8593	0.9472
17-AAG	RF	0.1087	1.678	1.6017	1.5755	1.547	1.5519	1.5611	1.6035	1.671	1.5987
	FRF	0.1058	1.662	1.5823	1.5418	1.5178	1.5106	1.5166	1.5492	1.6233	1.5629
VX-702	RF	0.0182	1.0286	0.94	0.8731	0.8194	0.7664	0.7161	0.6633	0.5946	0.8002
	FRF	0.0144	0.9724	0.8959	0.8398	0.7904	0.7437	0.6956	0.6431	0.5797	0.7701
AMG-706	RF	0.0248	1.2973	1.1542	1.0645	0.9935	0.9026	0.8418	0.7904	0.7485	0.9741

Table S2: Mean Absolute Error (MAE) between actual and predicted drug sensitivities (AUC and different IC's) for 2 methods; RF and FRF. In FRF, node cost is calculated using 8 IC regions. Here, results of all 140 drugs of GDSC database $v5$ are shown.

Drug Name	Model	AUC	IC_{10}	IC_{20}	IC_{30}	IC_{40}	IC_{50}	IC_{60}	IC_{70}	IC_{80}	Average
	FRF	0.0196	1.2103	1.0937	1.0077	0.9318	0.862	0.8004	0.7474	0.7164	0.9212
KU-55933	RF	0.028	1.1351	1.1014	1.0778	1.0601	1.054	1.0355	1.0323	1.0445	1.0676
	FRF	0.0256	1.1129	1.0832	1.0653	1.0508	1.0366	1.0265	1.0212	1.0236	1.0525
Elesclomol	RF	0.141	1.4571	1.4762	1.4966	1.5546	1.6021	1.657	1.7432	1.8698	1.6071
	FRF	0.1409	1.4824	1.4842	1.5052	1.5333	1.5754	1.6297	1.7157	1.8372	1.5954
BIBW2992	RF	0.0455	1.68	1.4938	1.3805	1.2748	1.1871	1.0968	1.0267	0.9668	1.2633
	FRF	0.0365	1.5605	1.3988	1.2878	1.1936	1.1062	1.0248	0.9605	0.9066	1.1798
GDC-0449	RF	0.0189	1.0277	1.005	0.9847	0.9597	0.9458	0.9244	0.8995	0.8784	0.9531
	FRF	0.016	1.0153	0.9884	0.9657	0.9442	0.9233	0.9023	0.8801	0.8541	0.9342
PLX4720	RF	0.0483	1.5692	1.4689	1.4215	1.3678	1.3222	1.2913	1.2586	1.2538	1.3692
	FRF	0.0414	1.5306	1.4469	1.3894	1.3402	1.2967	1.2556	1.2247	1.212	1.337
BX-795	RF	0.062	1.0441	1.0744	1.0978	1.1351	1.1623	1.2135	1.2705	1.3425	1.1675
	FRF	0.0674	1.0347	1.0469	1.0758	1.1086	1.1525	1.2035	1.2639	1.3461	1.154
NU-7441	RF	0.0275	1.1714	1.1346	1.1131	1.0902	1.0786	1.0547	1.0453	1.0503	1.0923
	FRF	0.0256	1.1641	1.1322	1.1102	1.0899	1.0707	1.0503	1.0344	1.0236	1.0844
SL 0101-1	RF	0.0179	1.1299	1.0358	0.9612	0.8958	0.8294	0.7733	0.7216	0.6886	0.8794
	FRF	0.0149	1.0816	0.9956	0.9277	0.8677	0.8122	0.7566	0.7017	0.6723	0.8519
BIRB 0796	RF	0.0305	1.5691	1.3311	1.167	1.0297	0.9419	0.867	0.8257	0.8295	1.0701
	FRF	0.025	1.4722	1.2753	1.132	1.0112	0.9085	0.8477	0.8105	0.8169	1.0343
JNK Inhibitor VIII	RF	0.0171	1.0403	0.9667	0.8984	0.8515	0.8095	0.7649	0.7258	0.704	0.8451
	FRF	0.014	1.0046	0.9326	0.8766	0.8282	0.7845	0.741	0.6997	0.6739	0.8176
681640	RF	0.0401	1.3126	1.2982	1.2978	1.2961	1.3022	1.3173	1.3265	1.3501	1.3126
	FRF	0.0372	1.3074	1.2959	1.2947	1.2963	1.3004	1.3045	1.3135	1.3416	1.3068
Nutlin-3a	RF	0.057	1.62	1.5644	1.5465	1.53	1.5188	1.5043	1.5174	1.5027	1.538
	FRF	0.0482	1.5596	1.5159	1.4888	1.4653	1.4444	1.4282	1.4193	1.4194	1.4676
PD-173074	RF	0.0296	1.334	1.259	1.1887	1.14	1.0905	1.0454	1.0031	0.9451	1.1257
	FRF	0.024	1.284	1.2063	1.1489	1.0974	1.0486	1.0029	0.961	0.9119	1.0826
ZM-447439	RF	0.0557	1.2916	1.2784	1.2863	1.2974	1.3067	1.3279	1.36	1.3987	1.3184
	FRF	0.0583	1.2759	1.26	1.2642	1.2778	1.2975	1.324	1.3599	1.4089	1.3085
RO-3306	RF	0.0325	1.2577	1.2367	1.2154	1.1892	1.1659	1.1581	1.1488	1.1331	1.1881
	FRF	0.0281	1.243	1.2111	1.1872	1.1656	1.1445	1.1255	1.1055	1.0845	1.1584
MK-2206	RF	0.0785	1.9689	1.7278	1.5932	1.4912	1.4365	1.4328	1.4115	1.4593	1.5652
	FRF	0.0796	1.9406	1.7131	1.5751	1.4836	1.4325	1.4036	1.4055	1.4503	1.5505
PD-0332991	RF	0.0761	2.601	2.1638	1.8999	1.715	1.582	1.4882	1.4441	1.4905	1.7981
	FRF	0.0794	2.5353	2.1459	1.894	1.6994	1.5679	1.4838	1.4526	1.4822	1.7826
NVP-BEZ235	RF	0.0832	1.1133	1.0286	1.0121	0.9897	0.9926	0.9951	1.0159	1.068	1.0269
	FRF	0.0885	1.1155	1.0373	1.003	0.9856	0.9827	0.9888	1.0111	1.0685	1.0241
GDC0941	RF	0.0946	1.7499	1.6538	1.5902	1.5603	1.5251	1.509	1.5179	1.5467	1.5816
	FRF	0.099	1.764	1.6516	1.5958	1.5593	1.5351	1.52	1.5238	1.5546	1.588
AZD8055	RF	0.0734	1.0321	0.949	0.9138	0.8951	0.8889	0.8979	0.9431	1.0052	0.9406
	FRF	0.0791	1.0391	0.9537	0.9104	0.8902	0.8863	0.9012	0.9375	1.0096	0.941
PD-0325901	RF	0.0812	2.3433	2.0098	1.8288	1.7015	1.6145	1.5304	1.5044	1.5131	1.7557
	FRF	0.0769	2.2177	1.9367	1.7638	1.6408	1.5438	1.4785	1.4531	1.4715	1.6882
SB590885	RF	0.0341	1.4614	1.359	1.3116	1.2473	1.1889	1.1352	1.1127	1.0636	1.235
	FRF	0.0256	1.3478	1.2691	1.2125	1.1601	1.1085	1.0632	1.0268	0.9883	1.1471
AZD6244	RF	0.0661	2.1526	1.9101	1.7448	1.6136	1.5017	1.4053	1.3401	1.2745	1.6178
	FRF	0.0601	2.1224	1.8862	1.7305	1.5989	1.4829	1.3849	1.3119	1.2494	1.5959
AZD6482	RF	0.0598	1.927	1.5917	1.4154	1.2863	1.208	1.167	1.1855	1.2647	1.3807
	FRF	0.0608	1.9065	1.6129	1.4284	1.3027	1.2172	1.1689	1.1828	1.2614	1.3851
CCT007093	RF	0.0186	1.1204	0.9965	0.9101	0.8314	0.7611	0.7174	0.6766	0.6513	0.8331
	FRF	0.0154	1.0653	0.9586	0.8785	0.8098	0.7475	0.6955	0.6514	0.6281	0.8043
EHT 1864	RF	0.0319	1.106	1.0437	1.013	0.9898	0.986	0.9899	0.9992	1.0379	1.0207
	FRF	0.0361	1.0963	1.0257	0.9957	0.9764	0.9726	0.9781	0.9965	1.0298	1.0089

Table S2: Mean Absolute Error (MAE) between actual and predicted drug sensitivities (AUC and different IC's) for 2 methods; RF and FRF. In FRF, node cost is calculated using 8 IC regions. Here, results of all 140 drugs of GDSC database $v5$ are shown.

Drug Name	Model	AUC	IC_{10}	IC_{20}	IC_{30}	IC_{40}	IC_{50}	IC_{60}	IC_{70}	IC_{80}	Average
BMS-708163	RF	0.0293	1.5469	1.3072	1.1329	0.9999	0.8894	0.8073	0.7513	0.7346	1.0212
	FRF	0.026	1.4647	1.2511	1.1	0.9713	0.8609	0.7795	0.733	0.7283	0.9861
PF-4708671	RF	0.0292	1.1894	1.0955	1.0303	0.9893	0.9533	0.9387	0.9444	0.9531	1.0118
	FRF	0.0324	1.1888	1.0877	1.0284	0.9863	0.9572	0.9354	0.9332	0.9525	1.0087
JNJ-26854165	RF	0.0497	0.9948	0.9099	0.8831	0.888	0.9249	0.9739	1.0338	1.1382	0.9683
	FRF	0.0542	1.0047	0.9112	0.879	0.8797	0.9081	0.9501	1.0172	1.1193	0.9587
TW 37	RF	0.0997	1.1688	1.0726	1.0199	1.0149	0.9969	1.0216	1.0692	1.1546	1.0648
	FRF	0.1119	1.1604	1.0587	1.0154	1.0005	1.0044	1.0245	1.0704	1.1612	1.0619
CCT018159	RF	0.0444	0.9253	0.9811	1.0433	1.0947	1.1444	1.198	1.269	1.3503	1.1258
	FRF	0.0455	0.8995	0.9516	1.0032	1.0567	1.1122	1.1703	1.239	1.3314	1.0955
AG-014699	RF	0.032	1.2495	1.2112	1.1764	1.1557	1.1313	1.113	1.1076	1.0955	1.155
	FRF	0.0295	1.2243	1.179	1.1516	1.1296	1.1092	1.094	1.0816	1.0694	1.1298



Figure S2: Distributions of MAE differences between FRF and RF predictions for the 50 bootstrap set show the robustness of FRF models.



Figure S3: Difference between MAE of FRF and MAE of RF for Average IC values for 70 drugs of GDSC (rest 70 in main manuscript).